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Programmatic and Individual-level Factors Associated with CD4 Cell 
Count at HAART Initiation and Survival Among Treatment-naïve 
Patients Initiating HAART in sub-Saharan Africa. 
Eduard Eduardo 
 People living with HIV in low- and middle-income countries, on average, initiate 
antiretroviral therapy (ART) in the advanced stages of the infection (i.e. when the CD4 cell count 
has dropped below the recommended threshold for ART initiation) despite more than a decade 
since the start of scale-up of ART [1-4].  Late ART initiation is associated with higher patient 
morbidity and mortality, increased risk of secondary transmission in the population and higher 
healthcare cost [5-10].  Knowledge of HIV status is a critical first step to initiate ART [11-14].  
Yet, half of the people living with HIV in sub-Saharan Africa are not aware of their status [15].  
The World Health Organization, the Joint United Nations Programme on HIV/AIDS and other 
institutions support adoption of active screening for HIV (i.e. testing asymptomatic people for 
HIV) to help identify and treat people living with HIV before progressing to the advanced stages 
of the infection [11, 14, 16, 17].  The role of active screening on earlier initiation of ART and 
patient survival has not been examined. In this dissertation, I reviewed and synthesized the 
literature to identify barriers to ART initiation operating in low- and middle-income countries.  I 
examined the role of active screening on patient CD4 cell count at ART initiation (a measure of 
HIV-disease progression) and survival, and investigated patient CD4 cell count at ART initiation 
as a potential mediator of the active screening-patient survival association.  The databases Ovid 
Medline, PsycINFO, CINAHL, Scopus and Cochrane Reviews were searched as part of the 
literature review. Of 265 articles reviewed, thirty-five met the eligibility criteria and were 




Marginal Cox Proportional models with robust sandwich estimators of variance were fitted as 
part of the statistical analyses for this dissertation.  Patient, programmatic, and contextual 
variables were considered for statistical adjustment.  Data for the analyses came from twenty-
nine HIV/AIDS care and treatment sites in Kenya, Uganda, and Tanzania participating in the 
International Epidemiologic Databases to Evaluate AIDS (IeDEA) initiative.  Patient level data 
were collected from 45,359 subjects who initiated ART between 2003 and 2008 in the twenty-
nine sites.  Site programmatic and contextual level data were collected via two structured 
questionnaires.  The critical review of the literature led to the identification of 1) individual, 
programmatic and societal-level barriers to HIV testing, enrolling into care, and ART initiation; 
and 2) barriers pertaining to lack of knowledge of HIV/AIDS and ART (e.g. HIV/AIDS 
symptomatology, ART benefits, ART toxicity), limited accessibility to services, poor quality of 
services, shortage of staff, and HIV-related stigma as the most prominent barriers.  Results of the 
analyses show that patients in sites with predominantly “Active Screening Entry Points” initiated 
ART, on average, with CD4 cell counts 24 cells/µL higher than patients in sites with mainly 
“non-Active Screening Entry Points.”  However, the gain in CD4 cell count did not translate into 
a statistically significant estimate of survival advantage for these patients [HR (95% CI): 0.82 
(0.64 – 1.06)] though the results are in the expected directions.  The modest gain in mean CD4 
cell count, and the documented benefits of active screening (e.g. high acceptability, increased 
number of patients tested and higher rate of identification of previously undiagnosed people 
living with HIV) support adoption of this intervention particularly in regions with a high HIV 
burden and where a low proportion of the population is unaware of their HIV status. 
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Three and a half decades after its emergence, the HIV epidemic remains a pressing public 
health challenges worldwide [18-20].  Globally, 35.3 million people are living HIV [15] and as 
many people have died since 1981 [21].  The impact of the epidemic has been disproportional 
with low- and middle-income countries accounting for most of the deaths and infections [15, 22, 
23].  In sub-Saharan Africa, the region most heavily affected [15, 23, 24], the epidemic has 
caused social and economic upheaval forcing numerous countries to declare AIDS a national 
health emergency [24].  In this region, AIDS has reversed gains in life expectancy [25, 26] and 
development [27], significantly decreased agricultural productivity [25, 28], and increased 
under-5 mortality [29] and widow and orphan-headed households [30]. 
After the advent of antiretroviral therapy (ART) in 1996, HIV infection changed from a 
death sentence to a chronic treatable condition [31, 32].  Efforts led by the United States’ 
President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund for AIDS, TB and 
Malaria and other international organizations [18], and strong political-will from low- and 
middle-income countries [15, 18, 27] have made ART available worldwide.  Today 9.7 million 
people in low- and middle-income countries are currently on ART when only 300,000 were on 
treatment in 2002 [33].  Furthermore, over the years the distribution of ART has become more 
proportional to the HIV burden as 78% of those on treatment reside in sub-Saharan Africa [34].  
The impact of these efforts is tangible. Approximately 5.5 million deaths have been averted in 
low- and middle-income countries since 1996, and HIV transmission has been reduced by 50% 
in some regions of these countries [15, 35].  In addition, labor productivity has increased, HIV-




The state of the epidemic today was aptly described in 2005 by Alan Berkman as “the 
best of times and the worse of times” [27].  Despite the progress, nearly 2 million adults in low- 
and middle-income countries acquire the virus each year [15].  Per the 2013 World Health 
Organization treatment guidelines, sixty-six percent of people who should be on ART in these 
countries are not receiving it, and millions are still dying each year [15].  Moreover, the full 
potential benefits of ART to individuals and the population as a whole have yet to materialize 
[38, 39] as most people living with HIV in these countries start treatment late (i.e. during the 
advanced, symptomatic stages of HIV disease when the CD4 cell count has dropped below the 
recommended threshold for ART initiation) [4]. 
Study Justification 
 Late ART Initiation 
CD4 cell count is an important immunologic marker of progression of HIV infection and 
a key predictor of mortality [40-42].  The current World Health Organization treatment 
guidelines recommend initiation of ART before the CD4 cell count reaches less than 500 
cells/µL [43].  Although it increased by as much as 83% relative to 2002, the median CD4 cell 
count at ART initiation for low-income countries was only 145 cells/µL by 2009 [4].  Middle-
income countries registered a similar trajectory during this period with an increase from 87 to 
155 cells/µL under the best case scenario [4].  Thus, even though ART has been available for a 
decade, patients in low- and middle-income countries generally start treatment at or below the 





The consequences of late ART initiation affect not only the individual but also the 
societies and economies of these countries.  Late ART initiation is associated with higher patient 
morbidity and mortality, increased risk of secondary transmission in the population and higher 
healthcare cost [5-10].  The mechanisms leading to late ART initiation are complex.  In the 
context of resource-limited settings, treatment availability has not translated into accessibility.  
As a decade of experience with ART delivery has shown, addressing late initiation of ART 
requires more than decreasing the cost of medication for low- and middle-income countries.  It 
necessitates analyzing the context in which delivery occurs so that barriers and facilitators are 
identified.     
 Causes of Late ART Initiation 
The causes of late ART initiation include both proximal and distal factors some of which 
are outside the control of individuals, and others which operate at different stage of the HIV 
treatment cascade (i.e. HIV diagnosis, enrollment in care, and ART initiation).  HIV testing, and 
care and treatment programs are operating in the context of underfunded, poorly integrated 
healthcare systems [45-47]. Furthermore, these programs aim to deliver health services to a 
population with high rates of poverty and who reside in settings with weak overall infrastructure 
(e.g. transportation, housing) [46-48].  Consequently, preventive and consistent care, which can 
aid in the timely identification of people living with HIV, is not the norm [46].  Knowledge of 
HIV status is a critical first step to engage those living with HIV in the treatment cascade [11-
14].  Yet, half of the people living with HIV in sub-Saharan Africa are not aware of their status 
[15] and would need to overcome personal and contextual barriers to receive a timely diagnosis.  




institutions have promoted adoption of active screening to compliment Voluntary Counseling 
and Testing [11, 14, 16, 17]. 
 Active Screening of HIV 
Active screening involves the routine offering of HIV testing and counseling to all 
individuals attending healthcare sites as part of standard care [11, 14, 17].  Unlike Voluntary 
Counseling and Testing, active screening is integrated within the healthcare system, and places 
the responsibility of initiating testing on the provider as opposed to the client who may be 
encumbered by lack of knowledge of HIV or perception of low risk [11, 17].  The existing 
literature shows that active screening increases the number of patients tested per provider and the 
rate of identification of HIV-positive individuals [11, 13, 49-51].  However, other studies show 
that a low proportion of those who test positive enroll into HIV care and treatment shortly after 
diagnosis.  It is unknown whether active screening helps reduce late ART initiation and as a 
result improves patient survival in the context of resource-limited settings. 
Methods and Objectives 
 Aims and Hypotheses 
This dissertation centers on 1) assessing the role of active screening, a widely adopted 
intervention in low- and middle-income countries [33], on patient CD4 cell count at ART 
initiation and survival, and 2) testing patient CD4 cell count at ART initiation as a mediator of 
the active screening-patient survival relationship.  It also reviews and synthesizes the literature to 
identify barriers to ART initiation.  The dissertation has the following aims and hypotheses: 
 AIM I:  To critically review and synthesize the literature examining barriers to timely 





 AIM II.  To determine the extent to which active screening is associated with 1) patient 
 CD4 count at ART initiation and 2) patient survival among treatment naïve patients.   
 
Hypothesis 1: HIV/AIDS care and treatment sites that conduct active screening will have 1) 
higher patient CD4 count at ART initiation compared with sites that do not 
conduct active screening.  
 
Hypothesis 2:  HIV/AIDS care and treatment sites whose primary entry points are associated 
with active screening (e.g. antenatal care units with Prevention of Mother to Child 
Transmission Programs) will have 1) higher patient CD4 count at ART initiation 
and 2) higher patient survival rates compared with sites whose primary entry 
points are not associated with active screening (e.g., Tuberculosis programs). 
 
Hypothesis 3:  The association between a site’s primary entry points and patient survival will 
be mediated, at least in part, by patient CD4 count at ART initiation.         
   
  Methodological Approach            
Chapter 2 addresses aim I (critical review of the literature).  I searched the databases 
Ovid Medline, PsycINFO, CINAHL, Scopus and Cochrane Reviews to identify individual-, 
programmatic-, and societal-level barriers to HIV testing, enrollment into pre-ART care, and 
ART initiation.  Eligible articles for this review met the following criteria: 1) describe barriers to 
HIV testing, enrollment into pre-ART care or ART initiation, 2) include adult men and non-




intravenous drug users, commercial sex workers which were not included in this analysis), 3) 
focus on low- and middle-income countries, 4) present findings from qualitative or quantitative 
studies or systematic reviews, and 5) are peer-reviewed.   Information on the year of publication, 
country/region study was conducted, study population, sample size, and study design was 
extracted. A list of all of the identified barriers was created, and the barriers were organized by 
treatment cascade stage (i.e. HIV testing, enrollment into pre-ART care, ART initiation), level of 
organization (i.e. individual-, programmatic-, societal-level), and theme 
(Knowledge/Information, Accessibility, Quality of Care, Stigma/Discrimination, 
Cultural/Gender Norms, Resources, Integration, and Policies).  Lastly, the number of times a 
barrier was identified was tallied to determine those more commonly reported.  
Aim II (relationship between HIV active screening, patient CD4 cell count at ART 
initiation, patient survival) is addressed in Chapters 3 and 4.  In Chapter 3, separate analyses 
were performed to tests the association between the exposure variables “Active Screening” and 
“Active Screening Entry Points” and the outcome patient CD4 cell count at ART initiation.  
HIV/AIDS care and treatment sites were classified by “Active Screening” status for the first 
analysis, and by “Active Screening Entry Points” status for the second analysis.  Mixed linear 
regression models with random intercepts were fitted for each analysis.  Patient-, programmatic-, 
and contextual-level variables were considered for statistical adjustment. 
In Chapter 4 I tested the association between “Active Screening Entry Point” and patient 
survival.  In addition, patient CD4 cell count at ART initiation was tested as a mediator of the 
“Active Screening Entry Points”- patient survival association.  Marginal Cox Proportional 




programmatic-, and contextual-level variables were also considered for statistical adjustment of 
the survival models. 
Patient and site level data were used for the analyses performed in Chapters 3 and 4.  A 
total of 45,359 patients who initiated ART between 2003 and 2008 in twenty-nine HIV/AIDS 
care and treatment sites provided data on demographic, clinical, laboratory and treatment status.  
The sites are located in Kenya, Tanzania and Uganda and participate in the International 
Epidemiologic Databases to Evaluate AIDS (IeDEA) (http://www.iedea-ea.org).  The IeDEA 
initiative is a worldwide research collaboration established in 2005 to identify optimal treatment 
and prevention strategies across diverse economic, geographical, and cultural settings.   
Programmatic and contextual data from participating sites were collected using two structured 

















Chapter 2. Individual, Programmatic, and Societal barriers Associated with Late ART 
Initiation in Low- and Middle-Income Countries: A Comprehensive Review of the 
















As we enter the fourth decade since its emergence, the HIV epidemic remains a major 
global public health challenge. Worldwide, an estimated 35.3 million people are living with HIV 
with ninety-five percent residing in low- and middle-income countries [15, 22, 23]. The advent 
of highly active antiretroviral therapy (ART) in 1996 dramatically changed the prognosis of the 
infection from a death sentence to a chronic treatable condition [31, 32]. The global effort to 
make ART available in low- and middle-income countries has had measurable success. 
Approximately 9.7 million people living with HIV are now on treatment in low- and middle-
income countries, an estimated 5.5 million AIDS-related deaths have been averted since 1996, 
and new HIV-infections among adults have been reduced by 30% since 2001 in part due to 
ART’s ability to reduce viral load [15, 33]. Furthermore, economic data show that the returns on 
investments of ART scale-up in low- and middle-income countries far exceeds its cost partly due 
to increased labor productivity, prevention of orphan care, and decrease of healthcare cost [31, 
36, 37]. 
Many challenges to control the epidemic remain, however, especially in low- and middle-
income countries. Approximately 36% of people in sub-Saharan Africa, the region most heavily 
affected by the epidemic, have never been tested for HIV and half of those living with HIV are 
not aware of their status [15, 52].  HIV/AIDS remains among the leading causes of disability and 
death in the region [19, 20].  Sixty-six percent (under 2013 WHO treatment guidelines) of the 
28.6 million people eligible for ART in low- and middle-income countries are not receiving 
treatment and thus are at increased risk of premature morbidity and mortality and of transmitting 
the virus [15].  An estimated 1.9 million new infections occur annually among adults in these 




income countries [15, 35].  ART patients in low and middle-income countries are three-to-four 
times more likely to die during the first year of treatment than those in high-income countries 
[5].  Thus, the full clinical, societal and economic potential of ART is yet to be achieved. At the 
heart of these challenges is late ART initiation (starting ART during the advanced, symptomatic 
stages of HIV disease).           
Since 2003, the World Health Organization has recommended that HIV positive adults 
and adolescents initiate ART before their CD4 cell count drops below 200 cells/µL to avoid the 
consequences of late ART initiation [41, 43, 44, 53].  The 2010 guidelines increased the 
threshold for ART initiation to 350 cells/µL and the 2013 guidelines to 500 cells/µL [43, 54].  
Late ART initiation is associated with higher morbidity and mortality, increased risk of 
secondary transmission and higher healthcare costs [5-10].  Yet, people living with HIV in low- 
and middle-income countries, on average, initiate treatment below 200 cells/µL despite more 
than a decade since the start of ART scale-up efforts in these countries [1-4].      
The barriers to late ART initiation include both proximal and distal factors. Some of 
these barriers exert their effect even before HIV is diagnosed. As shown by the conceptual 
diagram in Figure 1 [1], the HIV treatment cascade can be divided into three stages following 
HIV infection: HIV diagnosis, enrollment in care, and ART initiation.  Delays at any stage along 
the cascade can lead to late ART initiation. Four different possible scenarios (Pathways A-D) 
presented in Figure 1 lead us to three key conclusions which can be applied in investigating 




1) An early diagnosis soon after infection occurs is necessary to avoid late ART 
initiation. As shown by Pathway A, patients diagnosed in the advanced stages 
of the infection have no other alternative but to initiate treatment late.   
 
2) Although necessary, an early diagnosis is not sufficient to guarantee timely 
ART initiation.  Patients must be referred to and promptly linked with 
HIV/AIDS care shortly after diagnosis for continual monitoring until he or she 
is eligible for ART initiation.  As shown by Pathways B and C, delays in 
enrollment in pre-ART care and/or ART initiation will minimize the potential 
benefits of an early diagnosis.   
 
3) As shown by Pathway D, it is crucial that barriers to each stage of the treatment 
cascade are addressed to prevent late ART initiation.   
 
In summary, the scale-up of ART in low- and middle-income countries has led to 
considerable benefits for individuals and societies.  However, late ART initiation, which is 
associated with premature morbidity and mortality, secondary HIV-transmission, and higher 
healthcare cost, remains a formidable challenge.  Using Figure 1 as a guide, this review 
summarizes individual-, programmatic-, and societal-level factors identified as barriers to late 







 Three separate searches were conducted using the same set of databases to identify 
barriers to 1) HIV testing, 2) enrollment into pre-ART care, and 3) ART initiation.  The 
databases Ovid Medline, PsycINFO, Cochrane Reviews, CINAHL, and Scopus were searched 
(See “Search Strategy”, Appendix A for other databases considered).  We used the following 
search terms in different combinations to search the literature for barriers: “HIV”, “AIDS/or 
Acquired Immunodeficiency Syndrome”, “barriers”, “developing countries/or resource limited”,  
“low income countries”, “middle income countries”, and “Africa”; the following terms were 
used in conjunction with the aforementioned to subset the search to specific stages within the 
treatment cascade:  “testing”, “HIV testing”, “care/or patient care”, “HIV care”, “AIDS care”, 
“pre-ART”, “antiretroviral drugs/or HAART”, “HAART/Antiretroviral Therapy/Highly Active.” 
The search was limited to articles published from 1996 (marking the advent of ART) to August 
2012 and was limited to the English language. To supplement the search, we used the database 
search option “Find Similar” for the most relevant articles, reviewed the bibliography of review 
and other key articles, and added relevant articles from preliminary literature searches conducted 
in preparation for this manuscript (e.g. dissertation proposal).   
Study Selection 
 Selection of articles began by screening the titles and/or abstracts of articles identified 
during the search. Those articles whose subject matter did not pertain to the focus of this review 
were excluded. The remaining articles were then assessed for eligibility. Eligible articles met the 
following criteria: 1) describe barriers to HIV testing, enrollment into pre-ART care or ART 




solely specific subgroups (e.g. intravenous drug users, commercial sex workers which were not 
included in this analysis), 3) focus on low- and middle-income countries, 4) present findings 
from qualitative or quantitative studies or systematic reviews, and 5) are peer-reviewed. 
Review 
Eligible articles were reviewed to extract key study characteristics, and identify barriers. 
Information on the year of publication, country/region study was conducted, study population, 
sample size, and study design was extracted.  The barriers reported in each article were 
compiled, and then organized by whether they impacted HIV testing, enrollment into pre-ART 
care, and/or ART initiation in accordance with Figure 1. Within these three stages, the barriers 
were subdivided by whether they arise from individual, programmatic or societal level.  
Furthermore, within these levels, barriers were organized into eight themes 
(Knowledge/Information, Accessibility, Quality of Care, Stigma/Discrimination, 
Cultural/Gender Norms, Resources, Integration, and Policies). The themes were based on the 
similarities or patterns observed among the barriers reported.  For example, barriers pertaining to 
misconceptions of treatment, and unawareness of AIDS symptoms were grouped into the 
“Knowledge/Information” theme.  Lastly, we tallied the number of times a barrier was identified 






Study Selection and characteristics 
 A total of 265 articles were identified during the search with twelve of these identified 
via a review of bibliographies of other articles (see Figure 2, and Table 1 for a detailed list of the 
number of articles identified by search terms, selected for review and meeting the eligibility 
criteria). Eighty-two (30.9%) were kept after the initial screen. Of these, thirty-five (42.7%) met 
the eligibility criteria and were included in the final review.  
 Table 2 shows the key characteristics of the thirty-five articles. The years of publication 
range from 2001 to 2012. The study populations for thirty-three of the articles came from four 
regions: 1) sub-Saharan Africa (87.9%), 2) Asia (6.1%), 3) Middle East/Northern Africa (3.0%), 
and 4) the Caribbean (3.0%). Among the remaining two articles, one included twenty-nine 
countries from different parts of Africa (including Northern and sub-Saharan African) and the 
other an unspecified number of low- and middle-income countries in Latin America and Africa. 
South Africa was the focus for almost half (44.8%) of the twenty-nine articles from sub-Saharan 
Africa. The study populations included: adult men and women of varying HIV status, people 
living with HIV at different stages of the infection, community members, healthcare workers 
(e.g. counselors, physicians), NGO directors, health sites and healthcare systems. Most of the 
studies were quantitative (45.7%), followed by qualitative (31.4%), literature review (14.3%) and 
mixed qualitative/quantitative methods (8.6%).                 
Barriers to HIV Testing 
 Twenty-eight barriers to HIV Testing were identified (See Table 3). Some of the 
individual-level barriers varied depending on whether AIDS symptoms were apparent. Those 




55]. Among those with symptoms, lack of knowledge of HIV symptomatology, having a 
fatalistic attitude towards HIV/AIDS, or unwillingness to confront HIV/AIDS while on 
tuberculosis treatment inhibited those who may do so otherwise from getting tested [56-60]. 
Factors limiting an individual’s accessibility to testing included the cost of testing, and having 
inflexible work schedule [20, 55, 61, 62]. Endorsing AIDS-related stigma, and fear of 
experiencing stigma and of the consequences of testing positive (e.g. necessary changes in 
behavior and priorities, discrimination) were also identified as barriers [55-59, 63-67]. Other 
barriers included concerns about quality of care (e.g. protection of confidentiality, lack of 
empathy for those who test positive) [56-59]; and lack of autonomy for women who want to 
make decisions about their health [56, 64].  
 At the programmatic-level, limited access to testing due to lack of testing services 
particularly in rural areas, financial cost, inconvenient hours of operations and long waiting time 
were identified as barriers to testing [20, 55, 57, 68]. Shortage of staff, and lack of training and 
support (e.g. emotional support to reduce stress, medical supplies) for the staff reportedly 
discouraged individuals willing to get tested [58, 68]. Inadequate counseling rooms led to 
concerns of confidentiality when discussing test results [58]; and lack of services addressing 
barriers particular to men (e.g. men’s perception of risk taking as part of masculinity or 
healthcare is only for women or when one is symptomatic) was identified as limiting their 
participation [67]. 
 HIV/AIDS morbidity and mortality have diminished the public health labor force and 
thus has become a societal barrier [69]. Traditional views of masculinity (e.g. proving one’s 
manhood by not seeking medical care unless physical strength is weakened) were identified as 




policies towards people living with HIV discouraged individuals from seeking HIV testing [57, 
63, 65, 68, 70].       
Barriers to Enrollment into Pre-ART Care  
 Table 4 lists the barriers to enrolling into pre-ART care. A total of twenty-six barriers 
were identified. At the individual-level, not being aware of one’s HIV status, and again lack of 
knowledge of HIV/AIDS were identified as barriers this time to pre-ART care [7, 57, 62, 71, 72]. 
Concerns about the side-effects of ART and of those that could arise from alcohol consumption 
while on treatment also hindered enrolling into care [7, 9, 72]. Factors associated with age (e.g. 
knowledge of HIV/AIDS), sex (gender norms), low socioeconomic status (poverty), having 
inflexible work hours, distance to the health site, financial cost, and unfamiliarity with navigating 
the health system affected accessibility to care [7, 61, 62, 67, 71, 72]. Fear of stigma, and not 
being able to disclose one’s HIV status prevented people living with HIV from enrolling into 
care [7, 57, 59, 65, 72]. Lastly, concerns about the quality of care were again identified [71-73].  
 Programmatic-level barriers included the site’s limited hours of operation particularly for 
those employed [72]. Poor quality care at health sites (e.g. lack of confidentiality), and staff’s 
negative attitudes towards patients and co-workers suspected of being HIV positive discouraged 
people living with HIV (including health practitioners) from seeking care [58, 74]. At the 
societal, the limited pool of staff available for recruitment, as a consequence of HIV/AIDS, 
hindered the provision of quality care [69] . Traditional gender norms for both men and women 
were identified as social barriers as well as observed violence, stigma, and government policies 





Barriers to ART Initiation 
 Fifty-two barriers to ART initiation were identified and are listed in more details in 
Table 5. These include those identified earlier as barriers to testing and enrolling into care (lack 
of symptoms, knowledge, fear of side effects and waiting until TB treatment was complete 
before initiating ART) [9, 52, 57, 60, 65, 69, 74-77]. HIV-related morbidity as the infection 
progresses, financial strain (due to unemployment, lower socioeconomic status), level of 
affordability of treatment (including fees, ART and laboratory tests), and logistics (e.g. cost and 
access to transportation, visit waiting time) limited accessibility to treatment [10, 60, 61, 65, 69, 
72, 73, 76, 78-80]. Not receiving quality pre-ART care (lack of or inconsistent CD4 monitoring, 
sub-standard treatment from clinical staff), and changing health site after being diagnosed were 
also identified as barriers [9, 60, 65, 72-74, 81, 82]. Barriers related to cultural/gender norms 
such as the expectation of women to care for sick relatives were also reported [61, 67, 76, 77]. 
Lastly, HIV-related stigma and factors associated with stigma (e.g. lack of social support, 
inability to disclose, age and sex differences in disclosure) were again identified as barriers [9, 
10, 57, 60, 65, 72, 74-77, 80, 81]. 
 Programmatic-level barriers to ART initiation include high patient-provider ratio and 
high rate of staff turnover, the staff’s limited knowledge of ART and inability to train them, and 
shortages in medication and equipment [52, 60, 67, 69, 74, 83-85]. The staff’s disregard for 
protecting patient confidential information and poorly maintained health sites impacted quality 
of care and discouraged patients from seeking treatment [61, 69, 79]. Factors related to the 
management of patients and the staff were also identified. These included: 1) weak referral 
systems to bring diagnosed patients into care in a timely fashion, 2) sub-optimal system to 




care, 3) overly restrictive or inflexible requirements for ART preparedness (e.g. requiring 
“treatment buddies” and participation in adherence training before starting ART) even at the 
expense of losing patients too poor to cover the transportation cost of a “buddy” or too sick to 
complete adherence training before starting ART, 4) inconsistent application of the sites 
treatment guidelines for ART initiation, and 5) lack of task shifting policy to alleviate shortage of 
physicians [60, 74, 77, 83-85]. Barriers related with communication included the staff not 
speaking in the local native language of patients, and insufficient communication between 
counselors and physicians [52]. Stigma from staff towards patients and fellow staff discourages 
ART initiation for both patients and staff [52, 62, 70, 76, 77, 79]. The lack of collaboration 
between ART programs and tuberculosis treatment services or traditional healers were among 
the barriers associated with poor integration of services which as a consequence limited referral 
of HIV patients into care [52, 69, 71]. Lastly, persistent adoption of outdated national treatment 
guidelines (e.g. 2002 WHO ART guidelines which recommends treatment only for patients at 
CD4 cell counts below 200 cells/µL) was noted as a barrier to ART for patients eligible under 
current WHO ART guidelines [10, 83]; the absence of guidelines for the private sector also led 
to late treatment initiation [68].                  
 At the societal level, HIV-related morbidity and mortality has contributed to shortages of 
staff reducing the ability to address high patient-provider ratio and staff turnover rates [69]. Lack 
of knowledge of ART or propagation of inaccurate information about ART in the general 
population hinders initiation of treatment as it adds to preexisting levels of HIV-related fears 
[74]. Factors identified as barriers to HIV testing and enrollment into care (e.g. cultural and 
gender norms, and stigma) were also reported as societal barriers to ART [61, 63, 65, 67, 68, 70, 




limiting access to ART (e.g. unemployment, disparities in health) or enforcement of policies 
which inadvertently lead to unequal access to treatment (e.g. requirement of government-issued 
identification to receive ART) were reported as barriers [52, 61, 69, 70, 78, 79].  
Prevalent Barriers 
 The most commonly reported barriers to HIV testing pertained to the 
Stigma/Discrimination, 35% (10/28), and Accessibility, 18% (5/28) themes. These themes were 
also the most commonly reported for enrollment into pre-ART care, 27% (7/26) and 23% (6/26), 
respectively. Barriers pertaining to the Quality of Care, 31% (16/52), and Stigma/Discrimination, 






 Our literature review of thirty-five articles on the barriers to ART initiation in low- and 
middle-income countries show that the barriers to treatment 1) impact all of the stages on the 
treatment cascade (HIV diagnosis, enrollment into care, ART initiation), and 2) within each 
stage, operate at the individual, programmatic and societal-level. As hypothesized by the 
conceptual model (Figure 1), distal as well as proximal barriers to ART initiation were identified. 
Therefore, interventions which do not address barriers to HIV diagnosis and enrollment into pre-
ART care may fail to materially alleviate late ART initiation. Furthermore, interventions for late 
ART initiation should be multifaceted so that in addition to individual level factors (e.g. being 
aware of one’s HIV status, financial cost of care), programmatic deficiencies (e.g. poor quality of 
care, weak referral mechanisms) and societal barriers (e.g. stigma/discrimination towards people 
living with HIV, lack of knowledge of HIV in the community) are addressed concurrently. 
 We found that barriers associated with 1) lack of knowledge of HIV/AIDS and ART (e.g. 
HIV/AIDS symptomatology, ART benefits, ART toxicity), 2) limited accessibility to services, 3) 
poor quality of services, 4) shortage of staff, and 5) prevalent HIV-related stigma were identified 
across all three stages of the treatment cascade. Barriers associated with accessibility to services 
and stigma/discrimination were reported most often.  We argue that barriers associated with lack 
of knowledge of HIV/AIDS and ART, limited accessibility to services, poor quality of services, 
and shortage of staff (1-4 above) are a consequence of the weak or non-existing healthcare 





With few exceptions (e.g. Cuba’s healthcare system), healthcare systems in low- and 
middle-income countries are in a weak state and are poorly integrated due to underinvestment, 
decades of neglect by the government and implementation of structural adjustment programs 
[45-47]. Throughout the 1980s and 1990s, the International Monetary Fund’s and the World 
Bank’ promoted economic policies, known as structural adjustment programs, intended to 
achieve long-term economic growth in less developed countries [86, 87]. One of the components 
of these policies was for the national government to substantially reduce spending on health and 
welfare programs [27, 87, 88]. The consequences of these policies on an already underfunded 
systems serving predominantly impoverished populations were dire [87, 88]. These included 
reductions in demand for health services (as  household incomes decreased as a result of 
structural adjustment programs), decreases in access to health services, restrictions in hiring of 
staff even as the population increased or diseases spread, and cuts in maintenance of health sites 
and equipment [46, 86, 88]. It is no coincidence that these consequences are the same structural 
barriers identified in the literature.  
Though it would be impractical to recommend restructuring entire healthcare systems to 
address barriers to ART initiation, a sound understanding of the context in which HIV care and 
treatment was introduced is crucial to develop more comprehensive, multifaceted, effective 
public health approaches to address these barriers. Conditions such as HIV/AIDS require life-
long monitoring of people with the infection and continuous testing of those at risk for the 
infection. Unless the structural barriers which prevent large segments of the population in less 
developed countries from engaging consistently with the healthcare system are addressed, the 





HIV-related stigma was among the most commonly identified barriers in the literature. 
Stigma in the context of HIV has a long history. It was brought to the forefront by public health 
leaders (e.g. Jonathan Mann) as early as the mid-1980s [89]. Blame, and exaggerated fears of 
infectiousness and death have been associated with HIV/AIDS since emergence of the epidemic 
[57]. Further association of HIV with socially marginalized groups (e.g. gays, intravenous drug 
users, commercial sex workers) and culturally-sensitive topics such as sex and drug-use has 
amplified HIV-related stigma, and as shown by our findings create a powerful barrier at every 
stage of the treatment cascade and every level of organization [68, 70]. The notion that HIV-
related stigma would diminish as treatment becomes widely available is not supported by the  
frequency with which stigma was reported as a barrier even in the era of ART [65].  
Certain limitations should be noted. Given the nature of qualitative studies, we cannot 
determine the extent to which the identified factors hinder progression through the stages of the 
treatment cascade. Though results from quantitative studies can help shed light on this matter, 
those identified were cross-sectional in nature and thus should be interpreted with caution. We 
could not quantify the significance or prevalence of the barriers (e.g. attributable fraction 
associated with late ART) beyond the frequency with which they were reported.  To avoid 
limiting generalizability, we excluded studies focusing exclusively on important subgroups (e.g. 
migrant workers, commercial sex workers, intravenous drug users) who may face unique barriers 
to accessing care. Since neither of these important issues was the focus of our study, future 
studies should focus on 1) determining which of the identified barriers play a bigger role in 
limiting access to care, and 2) in assessing differences and similarities between these barriers and 
those faced by specific subgroups. The results were summarized for all low- and middle-income 




and cultural practices. Nonetheless, our findings are applicable to countries and/or regions 
affected by limited access to care, poverty, weak healthcare infrastructure and stigma. Lastly, as 
is common with most literature reviews we cannot rule out publication bias.   
Our study has several strengths. The articles identified covered four different regions 
which carry the biggest burden of the HIV epidemic. Studies from sub-Saharan Africa, the 
region with the highest HIV-prevalence, and South Africa, the country with the largest number 
of people living with HIV, were well-represented. The years of publication of the articles (2001 
to 2012) coincide with the period of major scale-up of ART in low- and middle-income 
countries. The studies included both quantitative and qualitative methods using a mixture of 
study designs (e.g. focus groups, in-depth interviews, surveys). Finally, our focus and results 
were comprehensive as we succeeded in identifying barriers operating at the individual, 






The scale-up of ART in low- and middle-income countries has been ongoing for over a 
decade and these efforts have helped reduce the consequences of the HIV-epidemic. Yet millions 
of people eligible for ART in these countries are not receiving treatment, and the risk of death 
even for those on ART is considerably higher than for patients in developed countries [5, 15]. 
Late ART initiation limits the potential of ART to diminish HIV-related morbidity and mortality, 
the incidence of new infections and economic loss [5-10]. The barriers contributing to late ART 
initiation impact all stages of the treatment cascade (HIV diagnosis, enrollment into pre-ART, 
ART initiation), operate at the individual, programmatic, and societal-level and include: 1) lack 
of knowledge of HIV/AIDS and ART (e.g. HIV/AIDS symptomatology, ART benefits, ART 
toxicity), 2) limited accessibility to services, 3) poor quality of services, 4) shortage of staff, and 
5) prevalent HIV-related stigma. Unless comprehensive, multifaceted interventions to late ART 
initiation are implemented or the healthcare system is strengthened, the availability of ART in 
the context of developing countries will not necessarily translate into accessibility for all who 
































Tables and Figures 









Figure 1. The Effects and Consequences of Barriers at Each Stage of the Treatment Cascade on 
Initiation of Antiretroviral Therapy for People Living with HIV in Low- and Middle-Income 
Countries. 
 
Source: Lahuerta M, et al. The Problem of Late ART Initiation in Sub-Saharan Africa: A Transient Aspect of Scale- 
up or a Long-Term Phenomenon? Journal of Health Care for the Poor and Underserved 2013, 24:359-383. 
 
Figure 2. Flow Chart of Studies Identified, Selected for Review and Included for Review of 
Literature on Barriers to Initiation of Antiretroviral Therapy in Low- and Middle-income 
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Table 1. Number of Articles Identified/Screened, Reviewed and Selected for Literature Review, by Stage of Treatment Cascade. 
   Search     No. of Articles No. of Articles No. of Articles    
Topic   Term Combinations Source Identified/Screened Reviewed  Eligible   
 
Barriers associated “HIV+Barriers+Africa”; Ovid Medline  13   7   3  
with HIV  “HIV+Barriers+ 
Developing Countries/or 
   Resource limited” 
 
Barriers to HIV “HIV+Barriers+Africa”; Ovid Medline  59   8   5   
testing   “HIV+Barriers+  
Developing Countries/ or 
   Resource Limited”;  
   “Barriers+Africa+HIV Testing”; 
   “Barriers+Developing Countries/or  
   Resource-limited+HIV testing”;  
 
Barriers to HIV “HIV+Barriers+Africa+ Ovid Medline  31   8   2 
and AIDS care AIDS or Acquired  
Immunodeficiency Syndrome 
+Care/or Patient Care”;  
“HIV+Barriers+Developing 
   Countries/Resource-limited+ 
   AIDS or Acquired  
Immunodeficiency Syndrome+ 
   Care/or Patient Care”; “Barriers+ 
   Africa+HIV Care”; “Barriers+ 
Developing Countries/ 
Resource-limited+HIV Care”; 










Table 1 (Cont’d). Number of Articles Identified/Screened, Reviewed and Selected for Literature Review, by Stage of Treatment 
Cascade. 
   Search     No. of Articles No. of Articles No. of Articles   
Topic   Term    Source Identified/Screened Reviewed  Eligible  
 
Barriers to HIV “HIV Testing+Barriers+ PsycINFO  24   6   5 
testing   Africa”; “HIV Testing+ 
Barriers+Developing 
Countries”;     
 
Barriers to ART “Barriers+Africa+Antiviral PsycINFO  24   9   3 





Barriers to ART* “Barriers+Developing  Ovid Medline  45   15   5 
   Countries+HAART/ 
   Antiretroviral Therapy/ 
   Highly Active”; “Barriers+ 
   Africa+HAART/ 
Antiretroviral Therapy/ 
   Highly Active”; 
    
Barriers to HIV “HIV+Testing+   Cochrane  20   1   0  













Table 1 (Cont’d). Number of Articles Identified/Screened, Reviewed and Selected for Literature Review, by Stage of Treatment 
Cascade. 
   Search     No. of Articles No. of Articles No. of Articles   
Topic   Term    Source Identified/Screened Reviewed  Eligible  
 
Barriers to HIV “HIV+Testing+Barriers+ CINAHL  4   1   0 
testing   Africa”; “HIV Testing+ 
Barriers+Africa” 
 
Barriers to HIV “HIV+Care+Middle  Scopus   12   2   0 
Care   income countries”; 
“HIV+pre-ART+  
   Low income countries”; 
    
Barriers to HIV Not Applicable  Bibliography  12   9   4 
Testing, pre-ART     of articles  
Care, and/or ART     reviewed 
 
Barriers to HIV Not Applicable  Dissertation  21   16   8 
Testing, pre-ART     proposal 
Care, and/or ART 
        
        







Table 2. Key Characteristics of the Thirty-five Articles Selected for the Literature Review. 
  Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Benotsch[63]  2008  29 Countries from  Directors of NGOs  29 HIV-Prevention Cross-Sectional 
Different Regions in       NGOs 
Africa  
 
Boyer[78] 2009  Yaoundé, Cameroon  ART and ART eligible N=707; 33% male;  Cross-Sectional 
        patients in six public  mean age: 35 years    
        hospitals 
 
Cleary[79] 2012  Four provinces representing ART patients aged ≥ 18 N=1,267;  Cross-Sectional 
    two urban and two rural  from 12 health sites in 26.5% male; 
    areas, South Africa  four provinces   mean age: 37.3 years  
 
Daftary[56] 2007  Durban, South Africa  HIV tested Tuberculosis N=21; 47.6% males; Phenomenological  
        patients (47.6% HIV+,  mean age: 31.9 years 
        23.8% unknown status) 
 
Dong[52] 2007  KwaZulu-Natal,   Healthcare staff, traditional  Unspecified  Case Study 
    South Africa   healers, patients, community  
members accessing care or  
residing near hospital and  
referral site 
     
Fitzgerald[75] 2009  KwaZulu-Natal,  HIV+ men enrolled in  8 HIV+ men;  Phenomenological 
        HIV treatment programs,  9 family members and Case Study 
their family members and  who provide support 
staff    for the men; information   
            on age not provided; 







Table 2 (Cont’d). Key Characteristics of Thirty-five Articles Selected for the Literature Review. 
   
Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Fox[73] 2010  Livingstone,   Confirmed and suspected N=800 (400 on ART, Cross-Sectional   
Choma District,  HIV+ individuals believed 400 not on ART);   
Lusaka, Zambia  to be eligible for ART  33% male; information 
            on age not reported. 
 
Fredlund[83] 2007  KwaZulu-Natal,  Nine clinics and one hospital N=10 health units Case Study   
South Africa   providing HIV care and  providing ART to  
treatment   1,311 patients 2 years   
after program initiation 
 
Govindasamy 2011  Western Cape,   Individuals newly diagnosed N=192; 59.5% males; Cross-Sectional   
[72]    South Africa   with HIV through a mobile mean age: 34.8 years. 
        unit 
 
Hatcher[7] 2012  Nyanza Province,  HIV+ adults aged ≥ 18 years N=483; 26.3% male; Cross-Sectional 
    Kenya    not previously enrolled  information on age 
in HIV care   not reported 
 
Kielmann[68] 2005  Pune, India   Private health practitioners N=27; 78% with Phenomenological  
            ≥ 10 years of 
            experience  
 
Kumarasamy 2007  India    Men and women in need Not applicable  Literature Review  
[61]        of HIV testing, care and 
        treatment 
 
Kumwenda 2011  Blantyre,   HIV+ postpartum ART N=803;  Cross-Sectional  







Table 2 (Cont’d). Key Characteristics of Thirty-five Articles Selected for the Literature Review. 
   
Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Loubiere[60] 2009  Various provinces,  Adult HIV+ patients   N=2,566;   Cross-Sectional 
    Cameroon   attending HIV services 28.7% males; 
            mean age: 36.7 years. 
 
Louis[71] 2007  Hinche, Haiti   HIV+ adults ≥ 18 years N=31; 51.6% males; Cross-Sectional and 
        in pre-ART care at   mean age: 39.5 years. Phenomenological 
        St. Therese Hospital 
 
Maman[64] 2001  Dar es Salaam,  HIV+/- men and women, N=15 women,  Phenomenological 
    Tanzania   and HIV serodiscordant  17 men and  
        couples   15 couples 
 
Meiberg[57] 2008  Polokwane,   Black undergraduate   N=72; 48.6% males; Phenomenological 
    South Africa   (86%) and postgraduate ages 18-36 years. 
        university students 
 
Morin[55] 2006  Epworth and   Community members  N=1,099;  Cross-Sectional and  
    Seke, Zimbabwe  attending six open-air  58.3% males;  Phenomenological 
        marketplaces   mean age: 29.2 years. 
 
Mqimeti[58] 2011  The Greater Tzaneen  Voluntary Counseling  N=60; 10% male; Cross-Sectional 
    Sub-District,    and Testing counselors 50% between ages 
    South Africa   working at hospitals and of 40-49 
        clinics 
 
Msellati[80] 2003  Abidjan and Bouake,  Pre-ART and ART patients N=711; 51.1% male; Cross-Sectional 








Table 2 (Cont’d). Key Characteristics of Thirty-five Articles Selected for the Literature Review. 
   
Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Mshana[65] 2006  Kisesa District,  Recently diagnosed HIV N1=12 HIV+ adults; Phenomenological  
    Tanzania   patients; community   16 groups of 8-12 and Case Study 
members   community members; 
    Information on age and  
sex not provided  
 
Muhamadi[74]2010  Iganga District,  ART patients and   N1=20 ART patients; Phenomenological 
    Uganda   community members  45% males;   and Case Study 
        living with or caring for  mean age: 36.4 years;  
        ART patients    N2=112 community 
            members; information 
            on age or sex not 
            provided. 
 
Murray[76] 2009  Lusaka, Zambia  HIV+ breastfeeding   N1=41 breastfeeding Phenomenological  
mothers participating in a  mothers; N2=33 key and Case Study 
cohort study of mother-to- informants (18 community 
child transmission of HIV members, 3 churh/home-based 
through breast milk and key care team members, 7 clinic 
informants (community staff members, 5 cohort study 
members, cohort study staff); information on sex and 
staff, health practitioners) age not provided. 
 
Nkuoh[20] 2010  Mbingo Village,  Adult fathers with at least N=252; 100% males; Cross-Sectional 
    Cameroon   one child   mean age: 49 years 
 








Table 2 (Cont’d). Key Characteristics of Thirty-five Articles Selected for the Literature Review. 
   
Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Opuni[81] 2009  Soweto and   HIV+ adults using clinical N1=510 HIV patients; Cross-Sectional 
    Johannesburg inner   HIV services in the public 20% male;  
city, South Africa  and private sector;   mean age: 35.7 years; 
    household members  N2= 777 household adults;  
        45% male,  
mean age: 35.7 years.  
 
Parkes- 2010  Masaka District,  ART eligible patients  N1=957 pre-ART Cross-Sectional and 
Ratanshi[77]   Uganda   in pre-ART care; ART patients; N2=48 Phenomenological 
        Patients   ART patients 
 
Parrott[9] 2011  Karonga District,  ART patients enrolled in  N=60; 46.6% male; Cross-Sectional and 
    Malawi   an HIV cohort study  median age: 37 years Phenomenological 
 
Pitpitan[66] 2012  Cape Town,   Individuals attending   N=2,572;   Cross-Sectional 
    South Africa   informal drinking   65.4% male; 
        establishments   mean age: 32.6 years 
 
Remien[67] 2009  Middle East and  Men and women in need Not applicable  Literature Review 
    North Africa   of HIV testing, care, and  
        treatment 
 
Sendagire[10] 2012  Kampala, Uganda  ART naïve and newly  N=326; 33% male; Cross-Sectional 
        registered ART patients  mean age: 34 years 
 









Table 2 (Cont’d). Key Characteristics of Thirty-five Articles Selected for the Literature Review. 
   
Publication Country/ 
References Year  Region   Population   Sample Size  Study Design  
 
Souteyrand 2008  Low- and Middle-  Healthcare systems  Not applicable  Literature Review 
[62]    income countries 
 
Tayler- 2010  Thyolo District,  Pre-ART and ART  N=1,633;   Prospective Cohort 
Smith[85]   Malawi   patients   34.1% males; 
            Mean age: 34 years 
 
Van Dyk[59] 2003  All provinces,   Community members  N=1,422;   Cross-Sectional 
    South Africa       37.8% male; 
















Table 3. Individual, Programmatic, and Societal Level Barriers to HIV Testing Reported in Low- 
and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Individual Knowledge/  1. Perceived low HIV risk/lack of symptoms;  
Information: 2. Lack of knowledge on HIV and benefits of      
treatment; having a fatalistic attitude;  
3. Unwillingness to deal with both TB and HIV 
simultaneously;  
 
Accessibility:  1. Not knowing where to test;  
2. Financial cost, time requirements;  
3. Inflexible work hours/occupation;  
 
Quality of Care         1. Concerns about the quality of care at health site 
(e.g. protection of confidentiality, training of staff, 
lack of empathy); 
 
Stigma/                       1. Experience and/or fear of stigma from 
Discrimination:         friends, partners, family (including being blame for 
infidelity, violence, abandonment);  
2. Fear of the consequences of a positive test result.  
3. Individual’s endorsement of AIDS-related 
stigma;  
 
Cultural/  1. Women’s lack of autonomy in making 
Gender Norms:  healthcare decisions.  
 
Programmatic  Accessibility:  1. Lack of testing service;  
2. Cost of testing;  
3. Inconvenient location and hours of operation;  
4. Long waiting time; 
  
Resources:  1. Shortage of trained counselors and health 
personnel;  
2. Inadequate training of staff;  
3. Lack of support (including emotional) for 
counselors;  
4. Shortage of materials;  
 
Quality of Care:  1. Inadequate counseling rooms to protect privacy; 





Table 3 (Cont’d). Individual, Programmatic, and Societal Level Barriers to HIV Testing 
Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Societal Resources:   1. HIV-associated morbidity and mortality among  
healthcare workers;   
 
Cultural/  1. Traditional masculine roles;   
   Gender Norms 
 
Stigma/   1.Community violence against people living with 
Discrimination: HIV;  
2. Discrimination towards people living with HIV 
and its acceptance by society;  
3. Negative portrayal of people living with HIV;  
4. Experience and/or fear of stigma from society;  
5. National- and/or local government-sponsored 
policies which discriminate against people living 






















Table 4. Individual, Programmatic, and Societal Level Barriers to Enrollment into Pre-ART Care 
Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Individual Knowledge/  1. Unaware of HIV status due to not testing or   
 Information:  returning for test results;  
2. Lack of physical symptoms;  
3. Lack of knowledge of HIV/AIDS symptoms 
and/or ART;  
4. Fear of treatment side effects and toxicity;  
5. Alcohol use;  
 
Accessibility:  1. Age and sex;  
2. Low SES and poverty;  
3. Women’s low SES and lack of access to 
household income;  
4. Inflexible work hours;  
5. Distance to the clinic;  
6. Perceived or actual cost of care;  
7. Unfamiliarity with the hospital’s system;  
 
Quality of Care:        1. Concerns about the quality of care at health site 
(e.g. protection of confidentiality, negative attitude 
of staff, training of staff);  
 
Stigma/                       1. Experience and/or fear of stigma/discrimination 
Discrimination:         from friends, partners, family, society (including 
being blame for infidelity, violence, abandonment);  
2. Lack of disclosure, not knowing how to and fear  
of potential consequences.  
 
Programmatic Accessibility:  1. Health site not accessible outside work hours;  
 
Quality of Care: 1. Lack of confidentiality;  
2. Inadequate pre-ART services;  
 
Stigma/  1. Attitudes and biases of healthcare workers 





Table 4 (Cont’d). Individual, Programmatic, and Societal Level Barriers to Enrollment into Pre-
ART Care Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Societal  Resources:  1. HIV-associated morbidity and mortality among  
healthcare workers; 
 
Cultural Norms: 1. Gender cultural norms (e.g. women to take care 
of the home);  
2. Traditional masculine roles;  
 
Stigma/ 1. Community violence against people living with 
Discrimination: HIV;  
2. Lack of social support in the community (e.g. 
neighbors, spiritual leaders);  
3. Experience and/or fear of stigma;  
4. National- and/or local government- sponsored 
policies which discriminate against people living 





Table 5. Individual, Programmatic, and Societal Level Barriers to ART Initiation Reported in 
Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Individual  Knowledge/   1. Lack of physical symptoms;  
Information: 2. Lack of knowledge or accurate information of 
ART and HIV/AIDS (fatalistic attitude, consulting 
solely with traditional healer, beliefs ART is 
harmful, misinformed of types of food that must be 
consumed for ART to be effective);  
3. Fear of treatment side effects and toxicity;  
4. Being on tuberculosis or other medical treatment;  
 
 
Accessibility:  1. Experiencing HIV-related disability;  
2. Lack of employment, food insecurity, lower 
socioeconomic status (based on education, income, 
poor housing);  
3. Perceived and actual financial cost of treatment 
including and in addition to ART (e.g. fees for 
consultations, medications for opportunistic 
infections, lab tests, loss of income due to clinic 
visit, more expensive treatment due to late ART 
initiation;);  
4. Logistics (cost and access to transportation, long 
wait time at health site);  
 
Quality of Care:  1. Not receiving necessary HIV-related care 
(HIV/baseline CD4 test, poor/no adherence to pre-
ART);  
2. Negative perceptions of clinical staff (fear of 
stigma, poor service);  
3. Changing HIV center after HIV diagnosis;  
 
Cultural/ 1. Women’s low SES and gender roles (lack of 
Gender Norms:  access to household income, expected to care for 







Table 5 (Cont’d). Individual, Programmatic, and Societal Level Barriers to ART Initiation 
Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Individual  Stigma/  1. Experience and/or fear of stigma or  
Discrimination:         discrimination from friends, partners, family 
(including being blame for infidelity, violence,  
abandonment);  
2. Lack of social support and inability to cope with 
HIV and necessary life-changing factors;  
3. Lack of disclosure and requirement to do so to 
access/adhere to ART;  
4. Alcohol use in relatives and fear HIV status will 
be disclosed when under the influence;  
5. Age and sex differences in disclosure, receipt of 
social support, and delays in enrollment into HIV 
care and ART initiation. 
 
Programmatic Resources:  1. High patient-provider ratio;  
2. Staff burn-out due to high patient volume and 
work demands;  
3. Staff’s poor or lack of knowledge of ART;  
4. Inability to properly train staff due to competing 
clinical demands;  
5. Shortages of supplies including HIV-
medications;  
6. Lack of CD4 count equipment on-site;  
 
Quality of Care:  1. Lack of confidentiality at health site;  
2. Poorly maintained clinics, including cleanliness; 
3. Poor referral mechanism leading to delays 
between HIV diagnosis and first ART consultation; 
4. Not counseling diagnosed patients on the 
importance of pre-ART care (e.g. treatment for 
opportunistic infection) and secondary transmission 
(including prevention of mother-to-child 
transmission) to keep them engaged in care;  
5. Sub-optimal system to avoid losses to follow-up 
(LTF) among patients in pre-ART care (e.g. 
instructing patients in early stages of the infection to 
return to care months after diagnosis, lack of tracing 
system, healthcare workers not prioritizing retention 
of less advanced patients, lack of personnel training 





Table 5 (Cont’d). Individual, Programmatic, and Societal Level Barriers to ART Initiation 
Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Programmatic Quality of Care: 6. Prioritizing patients with advanced disease at the 
expense of less advanced patients leading to long 
waiting time for service among the latter;  
7. Strict application of policies requiring completion 
of adherence training before ART initiation even for 
patients too ill to participate and/or engage;  
8. Strict application of policies requiring a 
“treatment buddy “ before ART initiation even for 
patients unemployed or too poor to cover 
transportation cost for someone else;  
9. Inconsistent application of treatment guidelines 
(e.g. ineligible patients treated and eligible not 
treated);  
10. Language barrier for non-English speakers (e.g. 
practitioners assessing ART knowledge of Zulu 
speakers in English and classifying them as not 
ready for ART);  
11. Lack of communication between counselors and 
physicians to address barriers to ART initiation;  
12. Not instituting task shifting from physicians to 
nurses;  
 
Stigma/  1. Staff’s stigma/negative attitudes towards HIV 
Discrimination: patients, other staff believed to be HIV-positive, 
and patients of low SES  
 
Integration: 1. High burden of tuberculosis (TB) and lack of 
integration between TB, HIV and other support 
programs;  
2. Exclusion of traditional healers;  
3. Labeling/designating clinics as “HIV Clinic”;  
4. Locating ART centers within larger district 
hospitals;  
 
Policies:  1. National treatment guidelines requiring  
advanced HIV stage to become eligible for ART;  








Table 5 (Cont’d). Individual, Programmatic, and Societal Level Barriers to ART Initiation 
Reported in Low- and Middle-income Countries, 2001-2012.  
   
Level of  
Organization  Theme      Barrier  
 
Societal  Resources:  1. HIV-associated morbidity and mortality among 
healthcare workers; 
 
Knowledge/  1. Lack of knowledge or accurate information of 
Information: ART and HIV/AIDS in the community (fatalistic 
attitude, beliefs ART causes death, cancer and 
infertility);  
 
Cultural/  1. Expectation of women to prioritize taking care of 
Gender Norms: the home, traditional masculine roles, and need of 
women to seek permission from men for treatment;  
 
Stigma/ 1. Experience and/or fear of stigma;  
Discrimination: 2. Lack of social support in the community (e.g. 
neighbors, spiritual leaders);  
3. National- and/or local government- sponsored 
policies which discriminate against people living 
with HIV;  
4. Community violence against people living with 
HIV;  
 
Policies:  1. Lack of effective government policies/programs 
(e.g. South Africa’s Disability Grant, user fees and 
cost recovery) to address unemployment, food 
insecurity, high prevalence of other infections, 
poverty;  
2. Disparity in health expenditures between the 
private and public health sector;  
3. Government policies such as the need for 
government-issued identification to receive ART 





















Chapter 3. Does Active Screening for HIV Lead to Earlier Initiation of Antiretroviral 






 The combined global effort to combat the HIV/AIDS epidemic has made tremendous 
progress in making antiretroviral therapy (ART) accessible to those in need.  In low- and middle-
income countries, where ninety-five percent of the HIV/AIDS burden is concentrated, 9.7 
million people were on ART by the end of 2012 representing an unprecedented increase relative 
to 2002 when only 300,000 were on treatment [33].  Among these are the 7.6 million people 
receiving ART in sub-Saharan Africa, the region most heavily affected by HIV/AIDS [34].  The 
global effort has helped avert an estimated 5.5 million deaths in low- and middle-income 
countries since 1996, and reduced transmission of HIV by as much as 50% in some regions [15, 
35] .   
Despite the progress, only 35% (under 2013 World Health Organization treatment 
guidelines) of those in need of ART in low- and middle-income countries are receiving it [15].  
Furthermore, those on treatment tend to initiate ART during the advanced, symptomatic stages of 
HIV disease (i.e. with a CD4 cell count below the recommended threshold for ART initiation) 
where the risk of morbidity and mortality are higher and opportunities to minimize transmission 
have been missed [5, 8, 40, 90-93].  Thus, the full potential benefits of ART are diminished [38, 
39].  A key contributing factor to late ART initiation is late diagnosis of HIV [29, 88, 94-97].  






Historically, HIV testing in resource-limited countries has been delivered through 
Voluntary Counseling and Testing units which are poorly integrated within the healthcare system 
and rely on an individual’s decision to seek testing [11, 51, 96].  This approach to testing 
combined with low perceptions of HIV-risk, fear of domestic violence and abandonment 
following a positive test result, high levels of stigma in the community, and limited accessibility 
to test units have led to underutilization of testing services [13, 50, 65, 70, 71, 99, 100].  As a 
consequence, only 40% of adults in sub-Saharan Africa are aware of their HIV status, and among 
at-risk age-groups, such as 15-24 year-olds, the proportion is as low as 15% for women and 10% 
for men [101].  At these levels, the likelihood of developing AIDS by the time of diagnosis 
and/or ART initiation increases considerably.  A study in Nigeria showed that among those 
tested, 22.1% and 49.7% received their HIV diagnosis with advanced (CD4 cell count: 200-349 
cells/µL) and severe (CD4 cell count: < 200 cells/µL) immunosuppression, respectively.  This 
study estimated that there were at least seven years between acquisition and diagnosis of HIV 
infection underscoring the severity of underutilization of testing services [102].        
The World Health Organization, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) and the US Centers for Disease Control and Prevention (CDC) support adoption of 
active screening to help identify and treat people living with HIV before progressing to the 
advanced stages of the infection  [11, 16, 17, 96].  Active screening involves the routine offering 
of HIV testing and counseling to all individuals attending healthcare sites as part of standard care 
[11, 17, 96].  This approach differs from the conventional model of Voluntary Counseling and 
Testing in that it is integrated within the healthcare system, and relies on the provider, rather than 





stigma associated with testing, and the dependency on an individual’s knowledge and risk 
perception to seek HIV testing [11, 17].   
In addition to primary health sites, active screening has been applied in HIV-related 
services, such as antenatal clinics, tuberculosis clinics and clinics for sexually transmission 
infections, all of which serve as critical gateways or entry-points to ART [11, 17, 33, 49].  Its 
adoption, however, has varied across these services and with it the degree of success in 
identifying HIV-positive individuals [33, 49, 103-105].  For example, active screening has been 
successfully adopted in prevention of mother to child transmission (PMTCT) programs in 
antenatal clinics but its application in tuberculosis clinics, where a high proportion of patients are 
co-infected with HIV, has been limited [49, 50, 103, 104].  Where adopted, active screening has 
been well accepted by clinicians and clients, and increased both the number of patients tested per 
provider and the rate of identification of HIV-positive individuals [11, 13, 49-51].  Despite these 
benefits, studies show that a low proportion of those who test positive enroll in HIV/AIDS care 
and treatment sites shortly after diagnosis [11, 51, 96].  It is well-documented that after 
overcoming challenges to testing those who test positive, including those identified early in the 
infection, confront additional barriers which lead to delayed enrollment into HIV-care thus 
contributing to late ART initiation.  These barriers range from poor referral mechanisms in the 
healthcare system to the inability of an individual to cope with a positive test result [65, 70, 77, 
95, 96].  Therefore, we cannot assume that the documented benefits of active screening (e.g. high 
acceptability and identification of HIV-positive individuals) translate into initiation of treatment 






In summary, despite successes in the scale-up of ART most patients in low- and middle-
countries initiate ART late (i.e. in the advance stages of the infection where CD4 cell counts tend 
to be below the recommended threshold for ART initiation).  Knowledge of HIV status is the 
first step to ART initiation.  Active screening has been shown to increase the proportion of 
individuals aware of their HIV status but whether it leads to initiation of ART earlier (i.e. at 
considerably higher CD4 cell counts) in the context of limited-resource settings merits further 
research.   
I used data from HIV care and treatment sites in sub-Saharan Africa to investigate the 
relationship between active screening and patient CD4 cell count at ART initiation (a measure of 
HIV-disease progression).  I hypothesize that HIV/AIDS care and treatment sites conducting 
active screening initiate patients at higher CD4 cell counts compared with sites that do not.  I 
also hypothesize that HIV/AIDS care and treatment sites receiving patients primarily from active 
screening entry points (e.g. antenatal clinics with Prevention of Mother to Child Transmission 
program) initiate patients at higher CD4 cell counts than sites whose patients come primarily 








 Data for this analysis come from the International Epidemiologic Databases to Evaluate 
AIDS (IeDEA) (http://www.iedea-ea.org).  The IeDEA initiative is a worldwide research 
collaboration established in 2005 to identify optimal treatment and prevention strategies across 
diverse economic, geographical, and cultural settings.  The consortium is composed of health 
sites and research institutions in several countries and regions: Asia/Pacific, the Caribbean, 
Central and South America, Canada, the United States, West Africa, Central Africa, East Africa 
and Southern Africa [106].  East Africa is the region providing data for this analysis.   
A site is composed of one or more clinics.  To participate in the initiative, sites must 1) 
provide ART to HIV/AIDS patients, 2) follow patients prospectively, 3) collect data 
electronically, and 4) adhere to a standardized protocol for data collection.  Patients aged 18 year 
or older at the time of ART initiation, who commenced ART between the years 2003 and 2008 
were eligible for this study.  Prior to analysis, the data were submitted electronically to the 
regional data center at Indiana University for merging and validation.  Collection of these data 
was approved by both Indiana University’s and Columbia University’s Institutional Review 
Boards (IRBs) as well as country (Uganda’s National Council on Science and Technology, 
Tanzania’s National Institute for Medical Research) and local (Moi University’s Institutional 
Research and Ethics Committee, Kenya Medical Research Institute, Mbarara IRB) IRBs. 
Twenty-nine HIV/AIDS care and treatment sites provided routinely collected data on 
45,359 patients who started ART during 2003-2008.  Thirteen (0.03%) patients who had CD4 
results outside the plausible range (i.e. > 1,600 cells/µL), and five (0.01%) patients whose last 
visit date was recorded as occurring before ART initiation were excluded.  The analytical sample 






   Patient information was routinely collected by the site’s staff where HIV/AIDS care and 
treatment was provided.  The staff followed a standard IeDEA-prescribed protocol thus the data 
were standardized across sites prior to submitting to Indiana University’s regional data center.  
Data included demographic (e.g. sex, date of birth, socio-economic status), clinical (e.g. WHO 
clinical stage, presence of tuberculosis disease and Kaposi’s sarcoma at ART initiation), and 
laboratory information (e.g. CD4 cell count at ART initiation, presence of anemia at enrollment).  
Site and Program-Level Data 
Information on the site’s characteristics and programmatic activities, including those 
related to the conduct of active screening and the sites’ primary entry points, was collected using 
two structured questionnaires: the East Africa Brief Follow-up Questionnaire and the IeDEA site 
assessment tool (See Appendix B).  Twenty-eight of the sites completed the East Africa Brief 
Follow-up Questionnaire and all twenty-nine sites the IeDEA Site Assessment Tool.   
The East Africa Brief Follow-up Questionnaire was used to classify sites as active or 
non-active screening for the period 2003 to 2008.  The questionnaire was utilized to collect 
information on factors such as 1) dates the site started providing HIV care, ART, and active 
screening services, 2) the population to whom active screening was offered (e.g. children, 
pregnant women, sex partners and/or other household members of ART patients), 3) occurrence 
of interruption(s) in the conduct of active screening, and 4) approaches to active screening.  Data 
were also collected on 1) the perceived level of stigma in the site’s catchment area, 2) the effect 
stigma may have had on uptake of HIV testing, and 3) the potential influence of Home Based 
Counseling and Testing on bringing subjects into care.  Home Based Counseling and Testing is a 
form of active screening carried out outside of the site but within its catchment area.  It was 





The IeDEA Site Assessment Tool was used to collect information on the site’s physical 
characteristics, programmatic activities and population served.  This included attributes such as 
1) type of site (e.g. health center/clinic, district/provincial hospital or teaching/national referral 
hospital), 2) policies followed (e.g. CD4 and WHO stage criteria to start ART, charging of fees 
for laboratory, medication and other services), 3) resources available (e.g. number of patient 
beds, number and types of providers and availability, tuberculosis diagnosis and treatment), and 
4) patient support services provided (e.g. adherence support, types of emotional, nutritional and 
pre-natal services) at the site.  Additional information on the population served (e.g. urban, rural, 
semi-urban residents) and the primary entry points (e.g. antenatal clinics, voluntary counseling 
and testing units, tuberculosis clinics) referring patients to the site was also collected.                    
Measures    
Outcome variables 
 The main outcome was the patient’s CD4 cell count at the time of ART initiation, a 
measure of disease progression.  The CD4 cell count measured closest to the date of ART 
initiation was used.  CD4 measurements taken no more than six months prior to or no more than 
fourteen days after the start of ART were considered.  CD4 cell count was analyzed as a log-
transformed continuous variable in regression models to better approximate the normal 
distribution.  CD4 values equal to 0 were changed to 1 prior to transformation. 
Exposure variables 
Two site-level exposure variables were used in separate analyses to assess active 
screening.  These included whether1) a site conducted active screening and 2) if its primary 
sources of patient referral were entry points likely to conduct active screening.  In the first 





2003-2008 period.  The classification was based on the 1) dates provision of ART and 
implementation of active screening were initiated (taking into account any sustained interruption 
of screening services), 2) dates of patient enrollment into care (relative to when active screening 
was initiated), 3) approaches to active screening employed, 4) group(s) to whom active screening 
was offered (e.g. sex partners, children, household members of ART patients), and 5) date(s) 
Home Based Counseling and Testing activities took place.  Sites which did not conduct active 
screening, initiated active screening in or after 2008 or limited screening only to children were 
classified as “non-Active Screening.”  Sites which 1) initiated active screening prior to or on the 
date provision of ART began, 2) started active screening prior to 2008, 3) enrolled 85% or more 
of their ART patients after active screening was initiated (See “Exposure Variables”, Appendix 
A for how this percentage was calculated), and 4) offered active screening to two or more adult 
groups associated with ART patients (e.g. sex partner(s), other household members) were 
classified as “Active Screening.”  Lastly, sites which 1) initiated active screening after provision 
of ART began but prior to 2008, 2) enrolled less than 85% of their ART patients after the start of 
active screening, and 3) limited active screening to one adult group associated with ART patients 
(e.g. sex partner(s), other household members) were classified  as “Partial Active Screening.”   
Based on information provided in the IeDEA Site Assessment Tool (See Question A15 
on p.183, Appendix B), the sites were also classified as having mainly “Active Screening Entry 
Points” or “non-Active Screening Entry Points” in the second analysis.  The classification was 
based on the site’s primary and secondary referral sources of patients.  Entry points where active 
screening was expected to be conducted included: Provider Initiated Testing and Counseling, 
Prevention of Mother to Child Transmission, and Other (“Research”).  Entry points where active 





and Outpatient Wards.  Voluntary Counseling and Testing units were treated as entry points 
where both active screening and diagnostic testing (not a form of active screening) may be 
conducted since these units test both subjects referred for routine testing or due to the appearance 
of symptoms.  A site was classified as having “Active Screening Entry Points” if 1) both the 
primary and secondary entry points included those expected to conduct active screening, 2) one 
of the active screening entry points was paired with Voluntary Counseling and Testing, or 3) 
both the primary and secondary entry points were Voluntary Counseling and Testing units.  Sites 
with Tuberculosis Clinic, Inpatient or Outpatient Ward as one of its entry points were classified 
as having “non-Active Screening Entry Points.” In five instances, two distinct entry points were 
ranked equally for either the most (1/5) or second (4/5) most common referral source of patients.  
In all but one instance, the ranking did not influence the classification of the site since the entry 
points were concordant with regard to active screening.  In the instance it did (site “EA14”), the 
third most common referral source of patients was used to determine the classification of the site.   
Potential Confounders  
 Patient, programmatic and site level variables hypothesized to be common causes of the 
exposure and outcome variable were considered for statistical adjustment.  The identification of 
these variables was based on a review of the HIV/AIDS literature and subject-matter knowledge.            
Patient-level Variables 
 Patient-level variables included sex (reference group: females), age at ART initiation 
(reference group: ages 30-35), and year of ART initiation (reference group: 2008) [5, 80, 92, 99].  
See “Potential Confounders”, Appendix A for more information on these variables and other 







Programmatic-level variables included presence of 1) nutritional support for all patients 
(reference group: absence), 2) outreach program for non-ART patients who missed visits 
(reference group: absence), 3) ART waiting list for eligible patients (reference group: absence), 
4) tuberculosis clinic on-site (reference group: sites referring patients off-site for tuberculosis 
treatment), and 5) tuberculosis treatment onsite but without an onsite tuberculosis clinic 
(reference group: sites referring patients off-site for tuberculosis treatment) [5, 107-109].  The 
site’s ART eligibility criteria for each World Health Organization clinical stage were also 
considered [110].    
The ART eligibility criteria were based on the required CD4 cell count to initiate ART 
per World Health Organization (WHO) clinical stage (criteria for WHO stages I and II 
(combined), III, and IV).  The CD4 thresholds used for each clinical stage were based on the cut-
points reported by sites for each stage, and the WHO ART guidelines in effect during the study’s 
follow-up period.  See Potential Confounders, Appendix A for more details on this construct, and 
other programmatic-level variables considered but excluded. 
Contextual-level Variables 
Contextual variables included 1) country location (Kenya (reference group), Uganda, or 
Tanzania), 2) site type (health center/clinic, district/provincial hospital (reference group), or 
teaching/national referral hospital, 3) patient population served (mainly urban, mainly rural 
(reference group), and in between urban and rural), and 4) Patient-provider ratio [29, 83, 95, 111-
114].  Note that due to a small number of sites located in Tanzania, country location was 
excluded from regression analyses but investigated as a potential confounding factor (see 





divided into four categories (ratios 0-4.0, 4.01-8.5, 8.6-11.99 (reference group), and 12-35.53).  
See Potential Confounders, Appendix A for more details on how patient-provider ratio was 
calculated and other contextual variables considered but excluded.         
Statistical Analysis 
 Data Validation and Descriptive Analysis 
Standard data validation was conducted to identify potential missing and implausible 
values and assess the distribution of continuous variables.  Descriptive statistics of key patient 
and contextual measures were calculated.  The mean (median for non-normally distributed 
variables) and range are reported as measures of central tendency for continuous variables, while 
frequencies and proportions are reported for categorical variables. 
Selection of Potential Confounders  
Selection of potential confounders was completed in three steps. First, based on a review 
of the literature and subject-matter knowledge Directed Acyclical Graphs (DAG) hypothesizing 
the relationships among the main exposure, outcome and potential confounders were drawn (See 
Figures 4 and 5).  Second, the strength and statistical significance of each bivariable association 
was measured (simple linear and logistic regression models, with random intercepts to account 
for clustering of patients within site, were used when needed) [115-118].  Lastly, variables 
associated (OR ≥ 1.20, mean CD4 count difference ≥ 20 cells/µL and/or P-value ≤ 0.10, in this 
instance) with at least two other variables were considered for statistical adjustment. The 
following variables were considered as potential confounders of the “Site Active Screening”-
“Patient CD4 Cell Count at ART Initiation” relationship: 1) Site’s patient-provider ratio, 2) 
Site’s country location, 3) Site’s ART eligibility criterion for WHO clinical stage I/II, and 4) 
Site’s ART eligibility criterion for WHO clinical stage III (See Figure 6); the following were 





Cell Count at ART Initiation” relationship: 1) Sex, 2) Site’s patient-provider ratio, 3) Site’s 
country location, and 4) Site’s ART eligibility criterion for WHO clinical stage I/II (See Figure 
7).   
Multivariable Analysis 
 For the regression models, a log transformation of the CD4 cell count was performed to 
better approximate the normal distribution.  Two-level mixed linear regression models were 
fitted with random intercepts for site to account for the correlation of patients within site (See 
“Justification for the use of Mixed Linear Regression Models and Assessment of Statistical 
Assumptions”, Appendix A for more information).  Two separate analyses were then performed: 
1) the CD4 cell count at ART initiation for patients in “Active Screening” sites was compared 
with those in “Partial” or “non-Active Screening” sites (see Sensitivity Analysis below for more 
information), 2) the CD4 cell count at ART initiation for patients in “Active Screening Entry 
Points” sites was compared with those in “non-Active Screening Entry Points.”     
The multivariable analysis began with a bivariable model to estimate the crude 
association between the main exposure and outcome variable.  DAG techniques as described by 
Greenland, Pearl, and Robins were employed to select the minimal set of potential confounders 
needed for adjustment [119].  Since no patient-level variable met the criteria for potential 
confounders, only one additional model adjusting for site level characteristics was fitted to test 
the association between “Active Screening” and “Patient CD4 Cell Count at ART Initiation.”  
The site level characteristics were patient-provider ratio, ART eligibility criterion for WHO 






In addition to the crude model, three multivariable models were fitted to test the 
association between “Active Screening Entry Points” and “Patient CD4 Cell Count at ART 
initiation.”  The first model adjusted only for the level-1 covariate (Sex).  The second model 
adjusted for level-2 covariates only (patient-provider ratio, ART eligibility criterion for WHO 
clinical stage I/II); and the third model adjusted for both the level-1 and leve-2 covariates.   
Neither the active screening nor the active screening entry points multivariable models 
could be adjusted for site’s country location due to the small number of sites in Tanzania (n=2) 
and Uganda (n=4) (See sensitivity analysis for how this potential confounder was assessed).  
Evidence of confounding was assessed by comparing changes in the sum of the intercept and 
main exposure beta estimates between the crude and the final model.  Presence of confounding 
was defined as a change of 10% or more relative to the crude estimates.   
Sensitivity Analysis 
 Additional analyses were conducted to assess the influence of various factors on study 
conclusions.  I calculated and compared the median time from patient enrollment into care until 
initiation of ART for active and non-active screening sites to assess whether the potential 
benefits of screening were negated by programmatic delays in treatment initiation.  
Approximately 17% of patients were missing CD4 cell count at ART initiation and thus did not 
contribute to the model results.  I compared the distribution of sex, and age and WHO clinical 
stage at ART initiation for patients with and without CD4 cell counts at ART initiation and 
assessed differences.  To assess the effect of not adjusting for country location, the final models 
were re-fitted limiting the data to sites in Kenya which accounted for 79% and 74% of sites and 
patients, respectively.  To assess the potential influence of patient socio-economic status, which 





status for East Africa (e.g. level of education, availability of electricity and piped water in the 
home) were added to the hypothesized DAGs.  I then assessed the need to adjust for these 
measures socio-economic status by determining the minimal set of variables needed to address 
confounding.  Lastly, to assess the potential impact of classifying the six “Partial Active 
Screening” sites (EA04, EA05, EA10, EA12, EA13, and EA33) as “non-Active Screening”, the 
active screening final model was fitted under two scenarios.  In the first scenario, patients who 
enrolled into care prior to the initiation of active screening were excluded from “Partial Active 
Screening” sites EA04, EA05, EA10, and EA13 and these sites were reclassified as “Active 
Screening” sites.  Since sites EA12 and EA33 were classified as “Partially” because active 
screening was limited to sex partners of ART patients, the classification for these sites remained 
as “non-Active Screening.”  In the second scenario, all six “Partial Active Screening” were 
excluded from the analysis.  The conclusions based on these scenarios were compared with those 
reached with the final active screening model.  All analyses were performed in SAS® Version 







 Patient and Contextual Characteristics of Study Population 
Table 1 shows that most of the 45,341 patients initiated ART in Kenya, which accounted 
for 33,586 (74%) patients in 23 (79%) sites, followed by Uganda with 9,737 (21%) patients in 4 
(14%) sites, and Tanzania with 2,018 (4%) patients in 2 (7%) sites.  Patients predominantly 
received care in teaching/national referral hospitals (40.9%) and district/provincial hospital 
(38.0%).  The percentage of patients initiated on ART increased each year until 2008 with the 
largest increases in earlier years.  The median age at the start of ART was 37 years (range 18 to 
88 years), and 64.3% were female.  Eighty-three percent of patients had a CD4 cell count at ART 
initiation, and the mean value was 87.2 cells/µL.  
As shown in Table 2, the total number of patients initiated on treatment during the six-
year period ranged from 55 to 8,592 among the twenty-nine sites.  The variation was partly due 
to differences in the number of years sites have been providing ART.  The patient median age 
per site ranged from 21 to 40 years, and at each site more than half of the patients were women 
(range 58.7-100%). 
Figure 1 shows the variation in the crude mean patient CD4 cell count and the proportion 
of patients missing CD4 cell count at ART initiation by site.  The crude patient mean CD4 cell 
count was 87.2 cells/µL (site range: 71.6 to 196.1 cells/µL).  The percent missing CD4 cell count 









Association between Active Screening and CD4 Cell Count at ART Initiation  
Table 3 lists the classification of each site by active screening.  One site (3.4%) did not 
provide information on active screening.  Twelve of the twenty-eight sites (42.8%) that 
responded to the follow-up questionnaire were classified as “Active Screening.”  The majority of 
ART patients (88% - 100%) at these sites enrolled into care after active screening practices were 
implemented.  The most common approach to HIV screening among these sites was Provider 
Initiated Testing and Counseling (11/12 or 91.7% of sites), followed by Prevention of Mother to 
Child Transmission (8/12 or 66.7% of sites) and Prevention with Positives (5/12 or 41.7).  With 
the exception of two sites, which offered treatment to two adult groups, all “Active Screening” 
sites offered testing to relatives, sex partner(s), other household members, and children of ART 
patients.   
Ten of the twenty-eight sites (35.7%) were classified as “non-Active Screening.”  With 
the exception of one site (EA34), none of the ART patients at these sites was exposed to active 
screening at the site since all were enrolled into care before active screening practices were 
implemented.  For site EA34, 2.4% of patients enrolled into care after active screening was 
initiated at this site.  Among the six sites classified as “Partial” (21.4%), two had 90% or more of 
their patients enrolled into care after active screening practices began.  However, these sites 
limited active screening to sex partner(s) of ART patient making it unlikely that a high 
percentage of the total patient population was actively screened for HIV.  For the other four sites, 
between 27.7% and 68.7% of patients enrolled into care after active screening began at the site.  
As described above, “Partial” and “non-Active Screening” sites were combined in the analysis.  





study site and was reported as a contributor to increased demand for secondary testing.  No other 
site performed Home Based Counseling and Testing between 2003 and 2008. 
Figures 2A and 2B show the crude mean patient CD4 cell counts at ART initiation for 
each site stratified by active screening.  The crude mean patient CD4 cell count at ART initiation 
were 89.7 (range: 77.7 to 170.5) and 85.6 (range: 71.6to 196.1) cells/µL for active and non-
active screening sites, respectively.  The site- and programmatic-level variables selected for 
statistical adjustment and their respective association with the exposure and outcome are listed in 
Table 4.  Relative to non-Active Screening sites, sites conducting active screening were more 
likely to have sites with the lowest (0.0-4.0) and highest (12.0-35.5) patient-provider ratios, and 
an ART guideline requiring a CD4 below 350 cells/µL to initiate ART for patients in WHO 
clinical stage III.  Conversely, they were less likely to have sites with the second lowest patient-
provider ratio (4.01-8.5) and an ART guideline requiring a CD4 below 200 cells/µL to initiate 
ART for patients in WHO clinical stages I or II.            
Table 5 presents estimates for the crude and adjusted random effects models.  In 
accordance with Figures 2A and 2B, the crude mean CD4 cell count for active and non-active 
screening sites were similar (99.8 vs. 98.7; p-value 0.91).  After adjusting for contextual 
potential confounders (patient-provider ratio, ART eligibility criterion for WHO clinical stage 
I/II, and ART eligibility criterion for WHO clinical stage III), the mean CD4 cell count for 
Active Screening sites was 92.6 cells/µL compared with 95.5 cells/µL (p-value 0.76) for non-
Active Screening sites.  Estimates for these models in the log scale are presented in “Results”, 






Association between Active Screening Entry-Points and CD4 Cell Count at ART 
Initiation  
Table 6 lists the primary and secondary source of patients and “Active Screening Entry 
Point” classification for each site.  Of the twenty-nine sites, twenty-two (75.9%) were classified 
as having primarily “Active Screening Entry Points” and seven (24.1%) were classified as 
having primarily “non-Active Screening Entry Points.”  Among “Active Screening Entry Points” 
sites, the most common primary or secondary entry point was Voluntary Counseling and Testing 
unit (24/44 or 54.5%) followed by Provider Initiated Testing and Counseling (11/44 or 25.0%) 
and Prevention of Mother to Child Transmission (9/44 or 20.5%).  Among “non-Active 
Screening Entry Points” sites, the most common entry point was In-patient Ward (5/14 or 35.7%) 
followed by Provider Initiated Testing and Counseling (3/14 or 21.4%), and a tie between 
Outpatient Ward and Voluntary Counseling and Testing (2/14 sites or 14.3% for each).  
Figures 3A and 3B show the crude mean patient CD4 cell count at ART initiation for 
each site stratified by Active Screening Entry Points.  The crude mean patient CD4 cell count at 
ART initiation were 93.3 (range: 77.7 to 196.1) and 80.1 (range: 71.6 to 124.5) cells/µL for sites 
with Active and non-Active Screening Entry Points, respectively.  As shown in Table 7, sites 
with Active Screening Entry Points were less likely to have male patients and the second highest 
(4.01-8.5) patient-provider ratios.  They were also more likely to have sites with the lowest 
patient-provider ratios (0.0-4.0) and follow an ART guideline requiring a CD4 below 200 
cells/µL to initiate ART for patients in WHO clinical stages I or II.      
 Table 8 presents the four random effects models fitted.  Similarly to Figures 3A and 3B, 
the crude model estimated a higher mean CD4 cell count for patients in “Active Screening Entry-





Adjusting for sex (Model 2) did not materially change the mean difference in CD4 cell counts 
(19.7 cells/µL vs. 19.6 cells/µL).  After adjusting for contextual and programmatic factors 
(patient-provider ratio, ART eligibility criterion for WHO clinical stage I/II) in Model 3, the 
mean difference between Active and non-Active Screening Entry Points sites increased to 23.5 
cells/µL (110.41 vs 86.9; p-value 0.004).  A similar mean difference is estimated in final Model 
4 (118.2 vs 94.5 or 23.7 cells/µL; p-value 0.005) which adjusts for patient, programmatic and 
contextual factors (sex, ART eligibility criterion for WHO clinical stage I/II, patient-provider 
ratio).  Estimates for these models on the log scale are presented in “Results”, Appendix A.             
Sensitivity Analysis 
The median time to ART initiation after enrolling into care was the same among Active 
and non-Active Screening sites (Active Screening Site Median (IQR): 56 days (21-140); non-
Active Screening Sites: 56 days (19-167)). Patients with and without a CD4 cell count at ART 
initiation were similar with respect to sex, WHO clinical stage and age at ART initiation.  
Limiting the data to sites in Kenya led to similar results and thus did not change study 
conclusions.  I hypothesized that patient socioeconomic status would be associated with the main 
exposure and outcome only indirectly via potential confounders site patient-provider ratio (active 
screening and active screening entry point models) and sex (active screening entry point model). 
Since these factors were adjusted in the final models, it is unlikely that lack of adjustment for 
socio-economic status influenced study conclusions. Similarly, neither the exclusion of “Partial” 
sites nor the re-classification of four of these sites to “Active Screening” changed study 
conclusions.  The results of these analyses are presented in Tables 11 – 15 under “Sensitivity 







 Our results show that when implemented in HIV-related programs (i.e. entry-points such 
as Prevention of Mother to Child Transmission), active screening is associated with earlier 
initiation of ART. The mean CD4 cell count for patients in sites with predominantly “Active 
Screening Entry Points” (e.g. Provider Initiated Testing and Counseling, Prevention of Mother to 
Child Transmission) was, on average, 24 cells/µL higher (118.2 cells/µL vs. 94.5; p-value 0.005) 
compared with patients in “non-Active Screening Entry Points” sites (e.g. Tuberculosis Clinics, 
In-patient Wards).  This modest increase may translate into better health outcomes, including 
improved survival, for these patients. Furthermore, this increase may lead to greater benefit for 
patients with the lowest CD4 cell counts given the shift in the CD4 cell count distribution that 
would result from higher population mean CD4 values. Therefore, the greatest impact of active 
screening may be on the most vulnerable patients (i.e. those with the lowest CD4 cell counts).  
 Our findings are in line with the limited number of studies testing the association between 
active screening and CD4 cell count at ART initiation in low- and middle-income countries. A 
study using data from Latin America, Asia and countries throughout sub-Saharan Africa showed 
that patients likely to have been screened for HIV had a mean CD4 cell count at ART initiation 
that was 30 cells/µL higher than those unlikely screened [99]. A South African study assessing 
the impact of provider-initiated testing on HIV-associated tuberculosis patients also found that 
screening was associated with a mean CD4 cell count 24 cells/µL higher at ART initiation [49]. 
Wachira et al study in Kenya measured a mean CD4 cell count of 190 cells/µL and 136 cells/µL 
for patients referred from provider-initiated testing and tuberculosis clinics, respectively [120]. 
Similarly to our findings despite implementation of active screening, patients in these studies had 





ART late. In a study in Haiti, the mean patient CD4 cell count at ART initiation for patients 
actively screened was 351 cells/µL [121].  This study lacked a comparison group and therefore 
we cannot confidently associate these results with active screening. However, the mean CD4 cell 
count is well-above what typical values observed in resource-limited settings.     
A number of factors may explain why we were not able to detect a statistical difference in 
mean CD4 cell counts at ART initiation (92.6 cells/µL vs 95.5 cells/µL; p-value 0.76) when 
active screening was implemented in HIV/AIDS care and treatment sites.  First, the literature 
shows that HIV-positive individuals in sub-Saharan Africa face multiple barriers (e.g. low 
socioeconomic status, overcrowded sites, physical accessibility of the site) at multiple levels 
(personal, site, and contextual, respectively) all of which can contribute to late ART initiation 
following a positive diagnosis [71, 89, 95].  It is possible that individuals diagnosed at active 
screening sites may have been diagnosed earlier in the infection but due to barriers to ART 
initiation started treatment as late as individuals diagnosed later in non-active screening sites.  
However, the analysis accounted for individual, site and contextual-level characteristics which to 
some extent correlate with barriers to ART initiation.   Furthermore, the median time to ART 
initiation relative to enrollment into care did not differ between active and non-active screening 
sites (See “Sensitivity Analysis”, Appendix A).  Nonetheless, other factors outside these areas 
(e.g. lack of transportation or access to existing modes of transportation, HIV-related stigma) 
were not considered.  
The grouping of “Partial” and “non-Active Screening” sites and the conduct of Home 
Based Counseling and Testing in the site’s catchment area may have raised the mean CD4 cell 
count of patients in “non-Active Screening” sites making it more similar to that of “Active 





CD4 cell count between active and non-active screening sites.  As shown in Table 3, although 
the percent was not as high as that of “Active Screening” sites, “Partial Active Screening” sites 
had a considerable number of patients enrolling into care after initiation of their active screening 
program, and thus likely exposed to screening.  Despite the percentages, neither the 
reclassification of four of the six “Partial” sites as “Active Screening”, following the removal of 
patients enrolled prior to initiation of active screening, nor the exclusion of all ‘Partial” sites 
changed study conclusions.  The conduct of Home Based Counseling and Testing in the sites’ 
catchment area was not a factor during the 2003-2008 period with the notable exception of one 
site.  This site (EA16), however, was an active screening site for the entire period of follow-up.   
Misclassification of sites by active screening status may have introduced bias.  The 
classification was largely based on recollection which is prone to recall bias.  The bias would 
have been non-differential and thus may explain the null findings for the Active Screening 
analysis (note that the Active Screening Entry Point classification was based on the most 
common sources of HIV patients which is less likely to be prone to recall bias).  Lastly, our 
findings may be due to the manner active screening is implemented in these two types of 
healthcare settings.  In HIV/AIDS care and treatment sites, active screening relies on ART 
patients to disclose their HIV status to sex partner(s), relatives or other adults household 
members and also convince them to get tested.  HIV-positive individuals in low- and middle-
income countries face multiple barriers to disclosure perhaps limiting the potential benefits of 
active screening [64, 70].  Furthermore, HIV-related stigma may prevent individuals from 
visiting a health site dedicated solely for the treatment of HIV/AIDS even if disclosure is not an 
issue [57].  At entry points (Prevention of Mother to Child Transmission) on the other hand, 





effective in accepting HIV testing.  Though we do not know what proportion of the sites’ patient 
population was screened, the literature suggests that the proportion screened in sites is likely less 
than that screened at entry points such as antenatal clinics [96, 122-124].  In addition, a portion 
of HIV positive individuals being tested for HIV in active screening sites may have done so out 
of personal concerns or the behest of a provider after the appearance of HIV-related symptoms.  
In this scenario, HIV testing constitutes diagnostic testing rather than active screening.  Though 
this scenario may also occur in entry-points (e.g. outpatient ward), it is unlikely to be as common 
among entry points like Prevention of Mother to Child Transmission programs, where HIV-
positive individuals tend to be younger, and asymptomatic and therefore at earlier stages of the 
infection [125].  Therefore, although both the site and the entry point presented in this scenario 
are conducting active screening, the degree of penetration of active screening differs and 
consequently the impact on CD4 cell count at ART initiation.       
There are some limitations to this study.  Nearly seventeen percent of the patients were 
missing a CD4 cell count at ART initiation and therefore were systematically excluded from 
multi-level models.  These patients, however, were similar to those with CD4 cell counts with 
regard to sex, age and WHO clinical status at ART initiation, a marker of disease progression.  
The programmatic and site level data collected through the IeDEA Site Assessment Tool reflects 
information at one point in time which may not fully reflect conditions during the entire follow-
up period.  Other unmeasured patient factors may have affected our results.  However, 
individual, site and contextual-level factors were considered during the analysis and adjusted as 
needed. In addition, the potential influence of patient socio-economic status, a prominent 
unmeasured variable, was considered during our sensitivity analysis and it is unlikely that this 





 This study has several strengths.  The data included a respectable number of sites all with 
a considerable number of patients initiating treatment.  The sites were from diverse geographic 
settings and data collection extended over several years.  Although most of the sites and patients 
came from Kenya, the findings likely apply to resource-limited settings with a generalized HIV 
epidemic.  The classification of the sites with regard to active screening was based on a host of 
factors (including qualitative data) assessing the HIV testing experience at the site and its 
catchment area during the follow-up period.  The completeness of the data was high for all the 
variables considered and/or adjusted in the models.  Individual, programmatic and site level were 
adjusted and/or considered for adjustment in multilevel models which is uncommon in these 
types of studies.  Finally, given the nature of the data collection (e.g. not from a cohort study 
with inclusion/exclusion criteria) our results represent real world conditions under which patients 
access and receive care.  The results are generalizable to resource-limited settings with sub-







Late ART initiation threatens the effectiveness of ART in reducing morbidity, mortality 
and HIV transmission  [38, 39].  Active screening has been adopted by most low- and middle-
income countries to identify people living with HIV and bring them into care before progressing 
to the advanced stages of the infection [96].  Similar to other studies, our analyses show that 
implementation of active screening is associated with higher CD4 cell counts at ART initiation in 
resource-limited settings [49, 99, 120].  This increase may translate into lower morbidity and 
mortality especially for those patients with the lowest CD4 cell counts who may benefit most 
from the shift in the CD4 cell count distribution resulting from higher population CD4 cell 
means.  Our results also show that additional interventions would be needed (e.g. home-based 
counseling and testing) to combat late ART initiation since active screening alone has not been 
shown to increase CD4 cell values to levels sufficient to prevent late ART initiation.  Future 
research should investigate 1) the average CD4 cell count at the time of HIV diagnosis 
particularly for screened patients to help determine the impact other factors may have in limiting 
the benefits of active screening, and 2) whether active screening results in improved survival for 
ART patients.    
 

















Tables and Figures 






Table 1. Distribution, Key Demographic and Clinical Characteristics of Patients Initiating 
Antiretroviral Treatment 2003 to 2008 in the 29 Sites in East Africa.  
                  
         No. (% or Min-Max) 
     
Patient Population by Country 
  Kenya        33,586 (74.1) 
  Uganda        9,737   (21.5) 
  Tanzania        2,018   (4.4) 
 
Patient Population by Site Type 
  Health Center/Clinic       9,539   (21.0) 
  District/Provincial Hospital      17,244 (38.0) 
  Teaching/National Referral Hospital    18,558 (40.9) 
 
Patient by Year of ART Initiation 
  2003         689      (1.5) 
  2004         3,012   (6.6) 
  2005         9,169   (20.2) 
  2006         10,931 (24.1) 
  2007         12,776 (28.2) 
  2008         8,764   (19.3) 
 
Median Age at ART Initiation     37  (18-88) 
 
Female Patients       29,118 (64.3) 
 
Patients with a CD4 Cell Count at ART Initiation   37,864 (83.5) 
 








Table 2. Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
            ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent  
(N=29) Country Site Type  Served (N=47,518) Initiation ART Initiation Female 
     
EA01  Kenya  District/  In-between 3993  2003-2008 36 (18-88)  66.0 
    Provincial Hospital Urban/rural  
 
EA02  Kenya  Health Center/Clinic Mainly  172  2007-2008 35 (20-69)  62.9 
       Urban 
 
EA03  Kenya  Health Center/Clinic Mainly  94  2007-2008 29 (19-49)  100.0 
       Urban 
 
EA04  Kenya  Teaching/  Mainly  8592  2003-2008 37 (18-81)  58.7 
    National Referral  Urban 
Hospital 
 
EA05  Kenya  District/Provincial In-between 324  2005-2008 39 (19-70)  73.2  
    Hospital  Urban/rural 
 
EA06  Kenya  District/Provincial In-between 583  2006-2008 38 (20-75)  66.6  
    Hospital  Urban/rural 
 
EA07  Kenya  District/Provincial In-between 322  2006-2008 38 (19-61)  66.2  
    Hospital  Urban/rural 
 
EA08  Kenya  District/Provincial In-between 788  2004-2008 37 (19-79)  65.5  
    Hospital  Urban/rural 
 
 








Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent  
(N=29) Country Site Type  Served (N=47,518) Initiation ART Initiation Female 
     
EA09  Kenya  District/Provincial Mainly  2023  2004-2008 38 (18-74)  70.0   
    Hospital  Urban 
 
EA10  Kenya  Health Center/Clinic Mainly  891  2007-2008 38 (20-78)  65.5 
       Rural 
 
EA11  Kenya  Health Center/Clinic In-between 2004  2004-2008 38 (18-75)  65.1 
       Urban/rural 
 
EA12  Kenya  Health Center/Clinic Mainly  788  2004-2008 38 (19-77)  62.4 
       Rural 
 
EA13  Kenya  District/Provincial Mainly  2443  2006-2008 37 (18-81)  64.5  
    Hospital  Urban 
 
EA14  Kenya  District/Provincial Mainly  142  2007-2008 35 (20-62)  64.1  
    Hospital  Urban 
 
EA15  Kenya  Health Center/Clinic In-between 1343  2004-2008 37 (19-76)  66.8 
       Urban/rural 
 
EA16  Kenya  Health Center/Clinic Mainly  2781  2003-2008 38 (18-76)  64.7 












Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent  
(N=29) Country Site Type  Served (N=47,518) Initiation ART Initiation Female 
     
EA17  Kenya  District/Provincial Mainly  2933  2005-2008 38 (18-80)  68.1  
    Hospital  Urban 
 
EA18  Kenya  District/Provincial In-between 538  2005-2008 36 (19-77)  62.5  
    Hospital  Urban/rural 
 
EA19  Kenya  Health Center/Clinic Mainly  782  2007-2008 33 (18-72)  66.8 
       Urban 
 
EA20  Kenya  Health Center/Clinic Mainly  55  2007-2008 21 (18-25)  77.1 
       Urban 
 
EA21  Kenya  District/Provincial In-between 1080  2006-2008 36 (18-77)  62.6  
    Hospital  Urban/rural 
 
EA22  Kenya  Health Center/Clinic Mainly  629  2004-2008 38 (18-78)  68.8 
       Rural 
 
EA23  Kenya  District/Provincial Mainly  286  2003-2008 30 (18-57)  73.4  
    Hospital  Urban 
 
EA27  Tanzania Teaching/National Mainly  607  2005-2008 40 (18-82)  61.0  
    Referral Hospital Urban 
 
 









Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
          ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent  
(N=29) Country Site Type  Served (N=47,518) Initiation ART Initiation Female 
     
EA28  Tanzania District/Provincial Mainly  1411  2005-2008 38 (19-82)  65.4 
    Hospital  Urban 
 
EA30  Uganda Teaching/National Mainly  339  2003-2008 32 (18-52)  69.6  
    Referral Hospital Urban 
 
EA32  Uganda Teaching/National Mainly  1363  2007-2008 35 (18-80)  60.5  
    Referral Hospital Rural 
 
EA33  Uganda District/Provincial Mainly  378  2003-2008 32 (19-71)  68.8  
    Hospital  Urban 
 
EA34  Uganda Teaching/National Mainly  7657  2003-2008 36 (18-80)  64.2  
    Referral Hospital Urban 
 









Figure 1. Crude Mean CD4 Count at ART Initiation of Patients Initiating Antiretroviral Therapy 
2003-2008 in the 29 Sites in East Africa. 
 
 
Facility EA01 EA02 EA03 EA04 EA05 EA06 EA07 EA08 EA09 EA10 EA11 EA12 
No. 
Patients 3993 172 94 8592 324 583 322 788 2023 891 2004 788 
% Missing 
CD4 15.3 2.9 1.1 14.1 19.1 13.2 9.6 11.8 13.1 23.1 11.7 12.1 
 
Facility EA13 EA14 EA15 EA16 EA17 EA18 EA19 EA20 EA21 EA22 EA23 EA27 
No. 
Patients 2443 142 1343 2781 2933 538 782 55 1080 629 286 607 
% Missing 
CD4 15.8 15.5 14.5 13.6 14.4 15.2 3.1 1.8 17.5 12.9 39.5 8.6 
 
Facility EA28 EA30 EA32 EA33 EA34 Total 
No. 
Patients 1411 339 1363 378 7657 45341 
% 
Missing 


















Earliest Year of 
Enrollment; (Percentage of 
ART Patients Enrolled 
After Initiation of Active 
Screening);  
No. ART Patients 
3HIV Testing Method Reported 
(Time Provided:  
E: At Enrollment,  
FU: During Follow-up, 
B: Both E and FU) 












































EA01 99/2004 07/2004 2002; (97.2); 3993 PITC (B), PMTCT (B), HBCT(B)     Yes 
EA02 05/2007 99/2007 2007; (95.9); 172 AD (B), PITC (B), FTA(B), PI (B)   x  Yes 
EA03 99/2006 99/2008 2002; (0); 94 PMTCT (B), FTA (B) x x x  No 
EA04 11/2001 99/2005 2001; (68.7); 8592 
HBCT(E), PITC (B),  
PWP (E), TP (B)     *Partial 
EA05 11/2005 99/2006 2002; (68.2); 324 PITC (E), HBCT (E),  PMTCT (B)     *Partial 
EA06 03/2006 99/2010 2003; (0); 583 
PITC (B), HBCT (E), 
PMTCT (B), PWP (B)     No 
EA07 03/2006 99/2010 2005; (0); 322 
PITC (E), VCT (B), 
HBCT (B), PMTCT (B) x  x  No 
EA08 11/2004 99/2009 2002; (0); 788 
PITC (B), HBCT (B), 
PWP (B), PMTCT (B)     No 
EA09 08/2004 08/2004 2002; (93.9); 2023 
PITC (E), PWP (B),  
TP (B), PMTCT (B)     Yes 
EA10 99/2007 99/2007 2005; (46.4); 891 VCT (E), PMTCT (B), HBCT (E)     *Partial 
EA11 99/2004 99/2004 2003; (94.0); 2004 
PITC (E), PMTCT (B), 
HBCT (E), PWP (F)     Yes 
EA12 07/2004 07/2004 2002; (95.0); 788 
PITC (B), VCT (E), 
HBCT (B), PMTCT (B) x  x  Partial 
EA13 99/2006 99/2007 2003; (27.7); 2443 
PITC (B), HBCT (B), 
PMTCT (B), PWP (B)     *Partial 
EA14 10/2007 99/2003 2005; (100); 142 PITC (E), PMTCT (B), VCT (E) x    Yes 
Notes:129 sites complete IeDEA Site Assessment Tool; 28 sites completed the East Africa Brief Follow-up Questionnaire. 
2“99” signifies that month was not reported. “N/A” signifies not available. 
3PITC= Provider Initiated Testing and Counseling, PMTCT= Prevention of Mother to Child Transmission, HBCT=Home Based Counseling and 
Testing, AD=Assisted Disclosure, FTA=Family Table Assessment, PI=Partner Involvement, PWP=Prevention with Positive, TP=Testing Partners, 
VCT=Voluntary Counseling and Testing, PEDs=Pediatric Clubs, CT=Children Testing 
4“Partial” were combined with “non-Active Screening” in the analysis.  
*Site was re-classified as “Active Screening” in sensitivity analysis after excluding patients enrolled into care prior to initiation of active 
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EA15 99/2004 99/2010 2002; (0); 1343 
PITC (E), VCT (B), 
HBCT (B), PMTCT (B) x  x  No 
EA16 11/2001 11/2001 2001; (100); 2781 
PITC (B), PMTCT (B), 
PWP (B), HBCT (E)     Yes 
EA17 12/2005 12/2005 2001; (92.5); 2933 
PITC (E), PWP (B), 
PMTCT (B), HBCT (B)     Yes 
EA18 N/A N/A N/A N/A N/A N/A 
EA19 04/2005 03/2005 2000; (99.9); 782 AD (B), PITC (B), FTA (B)      Yes 
EA20 12/2005 12/2005 2006; (100); 55 PITC (E), VCT (E), HBCT (F)     Yes 
EA21 08/2006 08/2006 2006; (97.5); 1080 
PITC (B), HBCT (E), 
PWP (B), PMTCT (B)     Yes 
EA22 7/2004 99/2009 2002; (0); 629 
PITC (E), PMTCT (F), 
PWP (B), HBCT (E)     No 
EA23 99/2004 12/2003 2003; (87.8); 286 VCT (E), PITC (E), PMTCT (B)     Yes 
EA27 07/2005 99/2010 2005; (0); 607  PITC (B), TP (B), PWP (B)   x  No 
EA28 06/2005 07/2009 2005; (0); 1411 FTA (B), PEDs (B)   x  No 




Screening Not Provided;  
(0); 1363 No method used N/A No 
EA33 99/1998 99/2003 2003; (92.9); 378 TP (B) x  x  Partial 
EA34 99/2004 99/2008 2002; (2.4); 7657 TP (B) x  x  No 
Notes: 129 sites complete IeDEA Site Assessment Tool; 28 sites completed the East Africa Brief Follow-up Questionnaire. 
2“99” signifies that month was not reported. “N/A” signifies not available. 
3PITC= Provider Initiated Testing and Counseling, PMTCT= Prevention of Mother to Child Transmission, HBCT=Home Based Counseling and 
Testing, AD=Assisted Disclosure, FTA=Family Table Assessment, PI=Partner Involvement, PWP=Prevention with Positive, TP=Testing Partners, 
VCT=Voluntary Counseling and Testing, PEDs=Pediatric Clubs, CT=Children Testing 





Figure 2A.  Crude Mean CD4 Count at ART Initiation for Sites Conducting Active Screening 
2003-2008 in East Africa. 
 
Figure 2B.  Crude Mean CD4 Count at ART Initiation for Sites not Conducting Active Screening 








 Table 4. Distribution of Potential Confounders and Associations with the Active Screening (Exposure) and Patient CD4 Cell Count at 
ART Initiation (Outcome). 
Sites with  Sites without  Association with Association with  
Active Screening Active Screening the Exposure  the Outcome  
 
         Mean CD4 Difference  
N (%)   N (%)   OR (P-value1)  (P-value) 
       
Site and Programmatic-level 
Level Characteristics 
Number of Sites    12 (100)  16 (100)  --   -- 
 
Site Patient-Provider Ratio 
0.0 to 4.0   5 (41.7)  1 (6.3)   15.0 (0.10)  +33.3 (0.01)  
 4.01 to 8.5   1 (8.3)   6 (37.5)  0.5 (1.00)  +21.1 (0.04)  
 8.6 to 11.99   2 (16.7)  6 (37.5)  Reference  Reference 
12.0 to 35.53   4 (33.3)  3 (18.8)  4.0 (0.31)  -1.7 (0.85)  
   
Site’s ART Eligibility Criterion  7 (58.3)  13 (81.3))  0.32 (0.23)  -23.0 (0.03) 
for Patients in WHO Clinical Stage 
1 or 2 (<200 vs 200+ cells/µL) 
 
Site’s ART Eligibility Criterion  4 (33.3)  4 (25.0)  1.22 (1.00)  -20.3 (0.05)  
for Patients in WHO Clinical Stage 3 
(<350 vs 350+ cells/µL) 
 











Table 5. Mean CD4 Values for Crude and Adjusted Mixed Model Comparing Patients in Sites 
with and without Active Screening.  
            
Model 1: Crude  Model 2: Adjusted 
Parameter     Mean CD4 (P-Value)  Mean CD4 (P-Value) 
 
Active Screening 
Yes     99.8 (0.91)   92.6 (0.76)  
   No     98.7 (ref)   95.5 (ref) 
 
Site Patient-Provider Ratio 
   0-4.0     ---    128.9 (0.11) 
   4.01-8.5    ---    119.6 (0.07) 
   8.6-11.99    ---    95.5   (ref) 
   12-35.33    ---    93.3   (0.83) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 200 cells/µL    ---    89.1 (0.61) 
   200+  cells/µL    ---    95.5 (ref) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 350 cells/µL    ---    93.0 (0.84) 









 Table 6. Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.            
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA01 Provider Initiated Testing and Voluntary Counseling and   Yes 
  Counseling    Testing (directly) 
 
EA02  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (via Referral)   Testing (directly)/Other  
       (Transfer In) [tied] 
 
EA03  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (directly) and    Counseling 
   (via Referral)[tied] 
 
EA04  Provider Initiated Testing and Inpatient Wards    No 
  Counseling 
 
EA05  Provider Initiated Testing and Prevention of Mother to Child  Yes 
  Counseling    Transmission Program within  
the Antenatal Clinic 
 
EA06  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral) 
 
EA07  Inpatient Wards   Provider Initiated Testing and  No 
Counseling 
 
EA08  Voluntary Counseling and  Provider Initiated Testing and  Yes 







Table 6 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA09  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
the Antenatal Clinic 
 
EA10  Voluntary Counseling   Provider Initiated Testing and  Yes 
  and Testing (directly)   Counseling 
 
EA11  Prevention of Mother to Child Voluntary Counseling and   Yes 
  Transmission Program within  Testing (directly) 
  the Antenatal Clinic 
 
EA12  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (via Referral)   Counseling 
 
EA13  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral) 
 
EA14 Voluntary Counseling and  Tied between Provider Initiated  
Testing (directly)   Testing and Counseling and TB  Yes     
Clinic followed by Voluntary  
Counseling and Testing (directly) 
 
EA15  Provider Initiated Testing  TB Clinic     No 








Table 6 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA16  Provider Initiated Testing  Voluntary Counseling and   Yes 
  and Counseling   Testing (directly) 
 
EA17  Provider Initiated Testing  Prevention of Mother to Child  Yes 
  and Counseling   Transmission Program within  
       the Antenatal Clinic 
 
EA18  Inpatient Wards   Voluntary Counseling and   No 
       Testing (directly) 
 
EA19  Voluntary Counseling and   Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral)/ 
       Other (Research)[tied] 
 
EA20  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 
EA21  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 









Table 6 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA23  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (directly)   Counseling 
 
EA27  Provider Initiated Testing  Prevention of Mother to Child  Yes 
  and Counseling   Transmission Program within  
       the Antenatal Clinic 
 
EA28  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 
EA30  Prevention of Mother to Child Voluntary Counseling and   Yes 
  Transmission Program within  Testing (directly) 
  the Antenatal Clinic 
 
EA32  Voluntary Counseling and  Outpatient Ward    No 
  Testing (directly) 
 
EA33  Provider Initiated Testing and Voluntary Counseling and    Yes 
Counseling     Testing (directly)/Prevention of Mother 
to Child Transmission Program within  










Table 6 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients          
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA34  Prevention of Mother to Child Inpatient Wards    No 
  Transmission Program within 










Figure 3A.  Crude Mean CD4 Count at ART Initiation for Sites With Active Screening Entry 
Points.  
 









 Table 7. Distribution of Potential Confounders and Associations with the Active Screening Entry Points (Exposure) and Patient CD4 
Cell Count at ART Initiation (Outcome). 
 
Sites with  Sites without  Association with Association with  
Active Screening Active Screening the Exposure  the Outcome  
Entry Points  Entry Points     
 
         Mean CD4 Difference  
N (%)   N (%)   OR (P-value1)  (P-value) 
       
Patient-level Characteristics 
Number of Patients     24,725 (100)  20,616 (100)  --   -- 
 
Male Sex     8,348 (33.8)  7,845 (38.1)  0.84 (<0.09)  -22.3 (<0.0001) 
 
Site and Programmatic-level 
Level Characteristics 
Number of Sites    21 (100)  8 (100)  --   -- 
 
Site Patient-Provider Ratio 
0.0 to 4.0   5 (23.8)  1 (12.5)  1.67 (1.00)  +33.3 (0.01) 
4.01 to 8.5   5 (23.8)  3 (37.5)  0.56 (1.00)  +21.1 (0.04) 
8.6 to 11.99   6 (28.6)  2 (25.0)  Reference  Reference 
12.0 to 35.53   5 (23.8)  2 (25.0)  0.83 (1.00)  -1.7 (0.85) 
 
Site’s ART Eligibility Criterion  16 (76.2)  5 (62.5)  1.92 (0.65)  -23.0 (0.03)  
for Patients in WHO Clinical Stage 
1 or 2 (<200 vs 200+ cells/µL) 
 







Table 8. Mean CD4 Values for Crude and Adjusted Mixed Models Comparing Patients in Sites with and without Active Screening 
Entry Points.  
                  
Model 1: Crude Model 2: Adj. for Model 3: Adj. for  Model 4: Adj. for 
     Mean CD4  Patient Factors Programmatic Factors  Patient and  
(P-Value)  Mean CD4  Mean CD4   Programmatic Factors 
        (P-Value)  (P-Value)   Mean CD4 
Parameter               (P-Value) 
     
Active Screening Entry Points 
   Yes    104.6 (0.03)  112.3 (0.04)  110.4 (0.004)   118.2 (0.005)  
   No       84.9   (ref)  92.7   (ref)  86.9    (ref)   94.5   (ref) 
 
Sex 
   Male    ---   73.3 (<0.0001) ---    74.7 (<0.0001) 
   Female   ---   92.7 (ref)  ---    94.5 (ref)  
 
Site Patient-Provider Ratio 
   0-4.0    ---   ---   102.3 (0.23)   109.4 (0.26) 
   4.01-8.5   ---   ---   106.3 (0.03)   115.8 (0.03) 
   8.6-11.99   ---   ---   86.9   (ref)   94.5   (ref) 
   12-35.33   ---   ---   84.0   (0.70)   91.5   (0.71)  
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 200 cells/µL   ---   ---   73.6 (0.11)   80.6 (0.12)  


















Directed Acyclical Graphs 

































































Chapter 4.  Does Active Screening for HIV Improve the Survival of Patients on 






 The positive trend in the scale-up of antiretroviral therapy (ART) in low- and middle-
income countries has continued for over a decade.  The number of HIV-patients receiving ART 
in these countries has increased from 300,000 in 2002 to 9.7 million by the end of 2012 [15, 33].  
As a result, an estimated 4.2 million deaths have been prevented, life expectancy has increased 
for those on treatment, and HIV-transmission in the general population has been reduced [15, 32, 
33].  Nonetheless, numerous challenges remain for those living with HIV in resource-limited 
countries.  AIDS continues to be a significant contributor to premature mortality, and ART 
patients are more likely to die of AIDS than their counterparts in high-income countries.    
In 2012 alone, 1.6 million people died of AIDS and over 90% of the deaths occurred in 
low- and middle-income countries [35].  Patients in low and middle-income countries are three-
to-four times more likely to die during the first year of ART than those in high-income countries 
[5].  Lack of knowledge of HIV-status and late ART initiation, which may be a consequence of 
not being aware of one’s status, are two major risk factors for AIDS-related mortality [1, 5, 12, 
15, 40, 126-128].  Yet in sub-Saharan Africa, the region most heavily affected by the HIV-
epidemic, half of those living with HIV are unaware of their status, and thus cannot benefit from 
the availability of ART [15, 33, 126].  In addition, the majority of the estimated 8 million HIV-
patients in sub-Saharan Africa start ART late (i.e. during the advanced, symptomatic stages of 
the disease where CD4 cell counts tend to be low) when the risk of death is considerably higher 
[1, 8, 91, 92].  CD4 cell count is an indicator of HIV disease progression.  Historically, the 
median CD4 count at ART initiation for patients in low- and middle-income countries has been 
below 200 cells/µL which is considered advanced by all of the World Health Organization ART 





To help combat these challenges, the World Health Organization and other public health 
institutions have recommended the adoption of active screening (e.g. Provider-Initiated Testing 
and Counseling) with subsequent linkage to HIV prevention, care and treatment [14, 16, 17, 
131]. Unlike Voluntary Counseling and Testing which is generally offered in stand-alone units 
and depends on a client’s request for HIV testing, active screening is offered by the provider as 
part of standard care and thus is less hampered by testing and treatment barriers related to 
stigma, discrimination and lack of general knowledge of HIV/AIDS [131].   
Active screening methods have been widely adopted since its recommendation seven 
years ago.  Of 102 countries surveyed in 2012, 95% have drafted policies for Provider-Initiated 
Testing and Counseling [33].  Studies show that Provider-Initiated Testing and Counseling has 
high acceptability by clinicians and clients, and increases both the number of patients tested per 
provider and the rate of identification of HIV-positive individuals [13, 49-51].  It has also been 
applied successfully in antenatal clinics as a means to 1) prevent mother to child transmission of 
HIV, and 2) enroll women on ART earlier than they would otherwise [33, 103, 132].  In previous 
analyses, I showed that patients in HIV/AIDS care and treatment sites receiving patients 
primarily from active screening HIV-related services (e.g. antenatal clinics with Provider-
Initiated Testing and Counseling for the prevention of mother to child transmission of HIV) start 
ART with modestly higher CD4 cell counts than those in sites receiving patients primarily from 
non-active screening entry points (e.g. Tuberculosis Treatment Programs, Inpatient Wards).  
However, whether these higher CD4 cell counts at ART initiation translate into improved 






I used programmatic, contextual and routinely-collected patient data from HIV care and 
treatment sites in sub-Saharan Africa to investigate whether implementation of active screening 
programs in the context of resource-limited settings lead to improved patient survival.  I 
hypothesize that HIV/AIDS care and treatment sites receiving patients primarily from active 
screening entry points (e.g. antenatal clinics with Prevention of Mother to Child Transmission 
program) have better patient survival than sites whose patients come primarily from non-active 
screening entry points (e.g. Tuberculosis Treatment Programs, Inpatient Wards).  Secondly, I 
hypothesize that this association is mediated, at least in part, by the patient’s CD4 cell count at 








 Data for this analysis come from the International Epidemiologic Databases to Evaluate 
AIDS (IeDEA) (http://www.iedea-ea.org).  The IeDEA initiative is a worldwide research 
collaboration established in 2005 to identify optimal treatment and prevention strategies across 
diverse economic, geographical, and cultural settings.  The consortium is composed of health 
sites and research institutions in several countries and regions: Asia/Pacific, the Caribbean, 
Central and South America, Canada, the United States, West Africa, Central Africa, East Africa 
and Southern Africa [106].  East Africa is the region providing the data for this analysis.   
A site is composed of one or more clinics.  To participate in the initiative, sites must 1) 
provide ART to HIV/AIDS patients, 2) follow patients prospectively, 3) collect data 
electronically, and 4) adhere to a standardized protocol for data collection.  Patients aged 18 year 
or older at the time of ART initiation, who commenced ART between the years 2003 and 2008 
were eligible for this study.  Prior to analysis, the data were submitted electronically to the 
regional data center at Indiana University for merging and validation.  Collection of these data 
was approved by both Indiana University’s and Columbia University’s Institutional Review 
Boards (IRBs) as well as country (Uganda’s National Council on Science and Technology, 
Tanzania’s National Institute for Medical Research) and local (Moi University’s Institutional 
Research and Ethics Committee, Kenya Medical Research Institute, Mbarara IRB) IRBs. 
Twenty-nine HIV/AIDS care and treatment sites provided routinely collected data on 
45,359 patients who started ART during 2003-2008.  Thirteen (0.03%) patients who had CD4 
results outside the plausible range (i.e. > 1,600 cells/µL), and five (0.01%) patients whose last 
visit date was recorded as occurring before ART initiation were excluded.  The analytical sample 






   Patient information was routinely collected by the site’s staff where HIV/AIDS care and 
treatment was provided.  The staff followed a standard IeDEA-prescribed protocol thus the data 
were standardized across sites prior to submitting to Indiana University’s regional data center.  
Data included demographic (e.g. sex, date of birth, socio-economic status), clinical (e.g. WHO 
clinical stage, presence of tuberculosis disease and Kaposi’s sarcoma at ART initiation), 
laboratory (e.g. CD4 cell count at ART initiation, presence of anemia at enrollment), and 
treatment status (e.g. lost to follow-up, dead, date of death) information.   
Site and Program-Level Data 
Information on site characteristics and programmatic activities, including those 
associated with a site’s primary entry points, was collected using the IeDEA Site Assessment 
Tool (see Appendix B).  The assessment tool was used to collect information on the site’s 
physical characteristics, programmatic activities and population served.  This included attributes 
such as 1) type of site (e.g. health center/clinic, district/provincial hospital or teaching/national 
referral hospital), 2) policies followed (e.g. CD4 and World Health Organization stage criteria to 
start ART, charging of fees for laboratory, medication and other services), 3) resources available 
(e.g. number of patient beds, number and types of providers and availability, tuberculosis 
diagnosis and treatment), and 4) patient support services provided (e.g. adherence support, types 
of emotional, nutritional and pre-natal services) at the site.  Additional information on the 
population served (e.g. urban, rural, semi-urban residents) and the primary entry points (e.g. 
antenatal clinics, voluntary counseling and testing units, tuberculosis clinics) referring patients to 






Measures    
Outcome variable   
 The main outcome was death.  Patient survival time was calculated in months and by 
taking the difference between the date of ART initiation and the date of death.  For patients 
known to have died but who lacked a recorded date of death, the last recorded site visit date was 
used as a surrogate date of death.  Patients who did not die were followed until their last visit, 
discontinued ART at the site, or up to closure of the database (in 2008 or 2009 depending on the 
site or HIV/AIDS program).  A patient was defined as being lost to follow-up if he or she did not 
have a clinic visit within three months of database closure without documented evidence of death 
or transfer to another site.  See “Outcome variable”, Appendix A for more details on patients lost 
to follow-up. 
Exposure variable 
The main exposure of interest was whether the site’s primary sources of patient referral 
were entry points likely to conduct active screening.  I utilized information provided in the 
IeDEA Site Assessment Tool (see Question A15 on p.183, Appendix B) to classify sites as 
having mainly “Active Screening Entry Points” or “non-Active Screening Entry Points.”  The 
classification was based on the site’s primary and secondary referral sources of patients.  Entry 
Points where active screening was expected to be conducted included: Provider Initiated Testing 
and Counseling, Prevention of Mother to Child Transmission, and Other (Research); entry points 
where active screening was not expected to be conducted included: Tuberculosis Clinics, In-
patient Wards, and Outpatient Wards.  Voluntary Counseling and Testing units were treated as 
entry points where both active screening and diagnostic testing (not a form of active screening) 





appearance of symptoms.  A site was classified as having “Active Screening Entry Points” if 1) 
both the primary and secondary entry points included those expected to conduct active screening, 
2) one of the active screening entry points was paired with Voluntary Counseling and Testing, or 
3) both the primary and secondary entry points were Voluntary Counseling and Testing units.  
Sites with Tuberculosis Clinic, Inpatient or Outpatient Ward as one of its entry points were 
classified as having “non-Active Screening Entry Points.” In five instances, two distinct entry 
points were ranked equally for either the most (1/5) or second most (4/5) common referral source 
of patients.  In all but one instance, the equal ranking did not influence the classification of the 
site since the entry points were concordant with regard to active screening.  In the instance it did 
(site “EA14”), the third most common referral source of patients was used to determine the 
classification of the site.      
Mediator Variable 
A patient’s CD4 cell count at the time of ART initiation, a measure of disease 
progression, was assessed as a potential mediator of the relationship between “Active Screening 
Entry Points and death.  The CD4 cell count measured closest to the date of ART initiation was 
used.  CD4 measurements taken no more than six months prior to or no more than fourteen days 
after the start of ART were considered (CD4 cell counts was analyzed as a log-transformed 







Potential Confounders  
 Patient, programmatic and site level variables hypothesized to be common causes of the 
exposure, outcome and mediator variable were considered for statistical adjustment.  The 
identification of these variables was based on a review of the HIV/AIDS literature and subject-
matter knowledge.   
Patient-level Variables 
 Patient-level variables included sex (reference group: females), age at ART initiation 
(reference group: ages 30-35), and year of ART initiation (reference group: 2008) [5, 80, 92, 99].  
See “Potential Confounders”, Appendix A for more information on these variables and other 
patient-level variables considered but excluded.   
Programmatic-level Variables 
Programmatic-level variables included presence of 1) nutritional support for all patients 
(reference group: absence), 2) outreach program for non-ART patients who missed visits 
(reference group: absence), 3) ART waiting list for eligible patients (reference group: absence), 
4) tuberculosis clinic on-site (reference group: sites referring patients off-site for tuberculosis 
treatment), and 5) tuberculosis treatment onsite but without an onsite tuberculosis clinic 
(reference group: sites referring patients off-site for tuberculosis treatment) [5, 107-109].  The 
site’s ART eligibility criteria for each World Health Organization clinical stage were also 
considered [110].   
The ART eligibility criteria were based on the required CD4 cell count to initiate ART 
per World Health Organization (WHO) clinical stage (criteria for WHO stages I and II 
(combined), III, and IV).  The CD4 thresholds used for each clinical stage were based on the cut-





follow-up period.  See Potential Confounders, Appendix A for more details on this construct, and 
other programmatic-level variables considered but excluded.     
Contextual-level Variables 
Contextual variables included 1) country location (Kenya (reference group), Uganda, or 
Tanzania), 2) site type (health center/clinic, district/provincial hospital (reference group), or 
teaching/national referral hospital, 3) patient population served (mainly urban, mainly rural 
(reference group), and in between urban and rural), and 4) Patient-provider ratio [29, 83, 95, 111-
114].  Note that due to a small number of sites located in Tanzania, country location was 
excluded from regression analyses but investigated as a potential confounding factor (see 
Sensitivity Analysis below for more how this issue was addressed).  Patient-provider ratio was 
divided into four categories (ratios 0-4.0, 4.01-8.5, 8.6-11.99 (reference group), and 12-35.53).  
See Potential Confounders, Appendix A for more details on how patient-provider ratio was 
calculated and other contextual variables considered but excluded. 
Statistical Analysis 
 Data Validation and Descriptive Analysis 
Standard data validation was conducted to identify potential missing and implausible 
values and assess the distribution of continuous variables.  Descriptive statistics of key patient 
and contextual measures were calculated.  Median values and ranges are reported as measures of 
central tendency for continuous variables not normally distributed, while frequencies and 






Selection of Potential Confounders  
Selection of potential confounders was completed in three steps. First, based on a review 
of the literature and subject-matter knowledge Directed Acyclical Graphs (DAG) hypothesizing 
the relationships among the main exposure, outcome, mediator and potential confounders were 
drawn (See Figure 3).  Second, the strength and statistical significance of each bivariable 
association was measured (to account for clustering of patients within sites, simple linear and 
logistic regression with random intercepts or Cox Proportional models with robust sandwich 
estimator of variance were used when needed) [115-118].  Lastly, variables associated (OR or 
HR ≥ 1.20 and/or P-value ≤ 0.10, in this instance) with at least two other variables were 
considered for statistical adjustment. The following variables were considered as potential 
confounders of the exposure-disease relationship: 1) Site type, 2) Site’s patient-provider ratio, 3) 
Presence of an ART waiting list for eligible patients, 4) Patient population served by site, 5) 
Site’s ART eligibility criterion for WHO clinical stage I/II, 6) Site’s country location, and 7) 
Sex; the following were considered as potential confounders of mediator-disease relationship: 1) 
Site type, 2) Site’s patient-provider ratio, 3) Age at ART initiation, and 4) Sex (See Figure 4). 
Multivariable Analysis  
First, I stratified the data by “Active Screening Entry Points” to calculate crude median 
survival time and incidence rate, and generate crude Kaplan-Meier survival curves.  Marginal 
Cox Proportional models (with robust sandwich estimators of variance to account for clustering) 
were then fitted (See “Assessment of the Statistical Assumptions for Cox Proportional Hazards 
Models”, Appendix A for more information).  The multivariable analysis began with a bivariable 
model to estimate the crude association between the main exposure and outcome variable. Four 





techniques as described by Greenland, Pearl, and Robins were employed to select the minimal 
set of potential confounders needed for adjustment [119].  Potential confounders which improved 
the precision of confidence intervals but which were not selected for the minimal set were also 
considered for adjustment.       
The first adjusted model included the main exposure variable with level-1 covariate only 
(Sex); the second adjusted model included the main exposure variable with level-2 covariates 
only (Site type, Site’s patient-provider ratio, Presence of a waiting list at site, Patient population 
served by site, Site’s ART eligibility criterion for WHO clinical stage I/II); and the third and 
fourth adjusted models included the main exposure with level-1 and leve-2 covariates (with and 
without the variable presence of a waiting list at the site).  To assess for evidence of confounding 
the betas estimated for the main exposure in the crude and the final model were compared.  
Presence of confounding was defined as a change of 10% or more in the main exposure beta.  
Lastly, adjusted survival curves based on the final model were generated comparing patients in 
active and non-active screening entry point sites.  The value used for each confounder was its 
corresponding mean.     
Assessment of Mediation 
We first measured the association between the main exposure and the mediator, and then 
between the mediator and the outcome [133].  Once these relationships were established, we 
assessed for effect measure modification of the main exposure and potential mediator.  This was 
performed by 1) stratifying on the levels of the main exposure and comparing the association 
between the potential mediator and the outcome by each stratified level, and 2) considering the 
size of the parameter and degree of statistical significance for an interaction term of the main 





sufficiently present to necessitate considering alternative tests of mediation (e.g. Sobel test), 
mediation was tested by fitting the final model plus the variable “Age at ART initiation” (the 
only potential confounder of the mediator-outcome relationship not included in the final model) 
with and without the potential mediator in an extended Cox model to meet the proportional 
hazards assumption.  Evidence of mediation was supported by a change of 10% or more in the 
direction of the null value for the main exposure beta once the mediator was added to the model 
[133].   
Sensitivity Analysis 
 Additional analyses were conducted to assess the influence on study conclusions of  
1) unadjusted potential confounders, 2) evidence of potential violation of the proportional 
hazards assumption, 3) outlier values of CD4 at ART initiation, and 4) lost to follow-up.  Due to 
the small number of sites in Tanzania (n=2) and Uganda (n=4) and proportion of missing values, 
the final model was not adjusted for site’s country location or measures of socio-economic 
status. To assess if study results were confounded due to exclusion of country location, I re-fitted 
the final model limiting it to sites in Kenya which accounted for 79% and 74% of sites and 
patients, respectively.  To assess the potential influence of patient socio-economic status, which 
was not adjusted due to large number of missing values, appropriate measures of socioeconomic 
status for East Africa (e.g. level of education, availability of electricity and piped water in the 
home) were added to the hypothesized DAGs.  I then assessed the need to adjust for these 
measures socio-economic status by determining the minimal set of variables needed to address 






During assessment of the proportional hazards assumption, the results hinted to potential 
violation of the assumption by the variables patient-provider ratio and site type.  Although upon 
re-assessment of the proportional hazards assumption adjusting for other variables in the model 
no evidence of violation was detected, I re-fitted the final model using extended and stratified 
Cox models assuming violation of the assumption by these variables was present.  The results 
and conclusions drawn from the refitted models were compared with those from the standard 
Cox Proportional model.  The Akaike Information Criterion (AIC) and evidence of improved 
precision in estimating the parameter for the main exposure were also considered during this 
comparison.    
To account for the potential influence of outliers, the mediation analysis was repeated 
operationalizing CD4 cell count at ART initiation using quartiles (reference group: log CD4 < 
3.95 (or 51 cells/µL)), and the clinically significant cut-point of 200 cells/µL (using the log CD4 
value: 5.30 cells/µL).  The cut-point of 350 cells/µL could not be tested due to small number of 
subjects with CD4 cell counts at ART initiation above this point.   
The potential introduction of bias due to early attrition was assessed through a subset 
analysis focused on patients who were lost to follow-up or died within the first year of ART 
initiation.  The proportion of patients lost to follow-up or recorded as dead within 12 months of 
ART initiation were compared between sites with active and non-active screening entry point.  
The last recorded CD4 cell count and the CD4 cell count at initiation for those lost to follow-up 
in the first year of ART were also compared between these sites to assess for mean differences. 
Lastly the final model was refitted assuming that among patients lost to follow-up within the first 
year of ART initiation, those from Active Screening Entry Point sites survived and those from 






 Patient and Contextual Characteristics of Study Population   
Table 1 shows that most of the 45,341 patients initiated ART in Kenya, which accounted 
for 33,586 (74%) patients in 23 (79%) sites, followed by Uganda with 9,737 (21%) patients in 4 
(14%) sites, and Tanzania with 2,018 (4%) patients in 2 (7%) sites.  Patients predominantly 
received care in teaching/national referral hospitals (40.9%) and district/provincial hospitals 
(38.0%).  The percentage of patients initiated on ART increased each year until 2008 with the 
largest increases in earlier years.  The median age at the start of ART was 37 years (range: 18 to 
88 years), and 64.3% were female.  The median survival time was 14.2 months (range: 0 to 75.6 
months), and the total person-time of follow-up was 809,860 months.  A total of 3,082 (6.8%) 
deaths were documented in the study population, and 13,253 (29.2%) patients were lost to 
follow-up.      
  As shown in Table 2, the total number of patients initiated on treatment during the six-
year period ranged from 55 to 8,592 per site among the twenty-nine sites.  The variation was 
partly due to differences in the number of years sites have been providing ART.  The patient 
median age per site ranged from 21 to 40 years, and at each site more than half of the patients 
were women (range: 58.7-100%). 
 Table 3 lists the primary and secondary source of patients and classification of active 
screening by site.  Of the twenty-nine sites, twenty-two (75.9%) were classified as having 
primarily “Active Screening Entry Points” and seven (24.1%) were classified as having primarily 
“non-Active Screening Entry Points.”  Among “Active Screening Entry Points” sites, the most 
common primary or secondary entry point was Voluntary Counseling and Testing unit (24/44 or 





of Mother to Child Transmission (9/44 or 20.5%).  Among “non-Active Screening Entry Points” 
sites, the most common entry point was In-patient Ward (5/14 or 35.7%) followed by Provider 
Initiated Testing and Counseling (3/14 or 21.4%), and a tie between Outpatient Ward and 
Voluntary Counseling and Testing (2/14 sites or 14.3% for each).   
Association between Active Screening and Patient Survival 
Figure 1 compares the crude survival probability of patients in active screening and non-
active screening entry point sites.  Patients in sites with primarily Active Screening Entry Points 
show worse survival than those in sites with primarily non-Active Screening Entry Points.  The 
patient and contextual variables selected for statistical adjustment and their respective 
association with the exposure and outcome are listed in Table 4.  Active screening sites had a 
lower percentage of male patients, of teaching/national hospitals and sites with a patient-provider 
ratio in the range of 4.01-8.5.  These sites were also less likely to serve predominantly non-urban 
patients and more likely to initiate patients with WHO clinical stage I or II only after reaching a 
CD4 cell count below 200 cells/µL.  Patients receiving ART in teaching/national hospitals and in 
sites with the lowest patient-provider ratio (0.0-4.0) were associated with lower rates of 
mortality.  Male patients and patients receiving treatment in sites serving predominantly non-
urban patients or sites requiring a CD4 cell below 200 cells/µL for ART initiation had higher 
rates of mortality.                        
Table 5 presents the five Cox models fitted.  In accordance with the crude Kaplan Meier 
curves, patients in Active Screening Entry Point sites had a rate of death 1.32 (95% CI: 1.03-
1.70) times higher than those in non-Active Screening Entry Point sites.  Adjusting for sex 
(Model 2) did not materially change the results.  However, following adjustment for 





waiting list at site, Patient population served by site, Site’s ART eligibility criterion for WHO 
clinical stage I/II) in Model 3, the mortality rate for patients in Active Screening sites decreased 
(HR: 0.83; 95% CI: 0.65-1.07) below that of patients in non-Active Screening Entry Point sites.  
The change is mainly attributed to the factors “Site type” and “Patient population served” (the 
addition of these two variables alone to the patient factor adjusted model results in a HR (95% 
CI) of 0.85 (0.66-1.09).  As described in the previous paragraph, patients who receive treatment 
in teaching/national hospitals and sites serving predominantly urban patients showed better 
survival and were unevenly distributed between Active and non-Active Screening Entry Point 
sites.  Among Active Screening Entry Point sites, patients from teaching/national hospitals only 
accounted for 3.8% of the population but for 85% of the non-Active Screening Entry Point 
population.  Similarly, patients in sites serving predominantly urban patients accounted for 
57.7% of the Active Screening Entry Point population but for 80% of the non-Active Screening 
Entry Point population.  Thus, the distribution of patients with better survival favored non-Active 
Screening Entry Point sites but after adjustment this source of confounding was addressed. 
  Models 4 (HR: 0.83; 95% CI: 0.63-1.09) and 5 (HR: 0.82; 95% CI: 0.64-1.06) adjust for 
patient, programmatic and contextual-level factors and show virtually no change in the estimates 
with one exception.  Model 5, the final model, shows that adjusting for presence of a waiting list 
at the site, which is not included in the minimal set of variables needed for adjustment, leads to 
approximately a 9% improvement in the precision of the 95% confidence intervals (width 
decreases 8.7% from 0.46 to 0.42 points).  Despite the improved precision, the results of the final 
and nearly all other adjusted models narrowly miss statistical significance.  Lastly, Figure 2 





model (Model 5).  The figure displays the better survival probability for patients in sites with 
predominantly Active Screening Entry Points.    
Assessment of CD4 Cell Count at ART as a Mediator of the Association Between Active 
Screening Entry Point and Patient Survival  
The results presented in Table 6 establish that there are significant associations between 
Active Screening Entry Point and CD4 cell count at ART initiation, and CD4 cell count at ART 
initiation and patient survival.  The results of the stratified analysis (Table 6) and those of a test 
for multiplicative interaction (not shown; p-value 0.58) suggest that the association between the 
proposed mediator and the outcome do not vary appreciably by levels of the main exposure.  As 
shown in Table 7 adding the mediator patient CD4 cell count at ART initiation and age at ART 
initiation, a potential confounder of the mediator-outcome association, to the final model led to a 
decrease towards the null of 64.7% [-0.19493-(-0.06864)/-0.19493] for the beta estimate of the 
main exposure.  The change translated to an increase in the Hazard Ratio towards the null value 
from 0.82 to 0.93.  
Sensitivity Analyses 
Adjusting for country location by limiting the data to sites in Kenya, and fitting separate 
stratified Cox models assuming presence of violation in the Proportional Hazards Assumption by 
patient-provider ratio and site type did not lead to improvements in the models or changes in 
study conclusions (See Table 8, “Results – Sensitivity Analyses”, Appendix A for more 
information).   
I hypothesized that patient socioeconomic status would be associated independently with 
the main exposure and outcome directly and via potential confounders site type, site patient-
provider ratio, sex, and patient's degree of adherence to ART. With the exception of ART 





influence of patient socioeconomic status on the study findings given the hypothesized 
relationships among these variables.  However, patient ART adherence, which is known to be 
associated with survival, was unmeasured and could not be adjusted indirectly through other 
variables. If sites with non-Active Screening Entry Points have a considerably higher proportion 
of patients with lower socioeconomic status and these patients indeed have worse survival, not 
adjusting for this factor may lead to a protective hazard ratio as observed in our results.  
The test for mediation using a stratified model with CD4 cell count at ART initiation 
operationalized as quartiles, to account for the potential influence of outliers, did not change 
study conclusions regarding mediation. However, when the mediation variable was dichotomized 
at 200 cells/µL, the results did not support evidence of mediation (See Table 9, “Results – 
Sensitivity Analyses”, Appendix A for more information).  
Within one year of ART initiation, 8,680 patients were lost to follow-up and 2,469 were 
recorded as dead. The proportion lost to follow-up (19.2% vs. 19.0%; OR: 0.99 (0.7-1.5)) or 
recorded as dead (6.0% vs. 4.8%; OR: 1.03 (0.6-1.8)) did not differ materially between active 
and non-active screening sites (See Table 10, “Results – Sensitivity Analyses”, Appendix A for 
more information). The mean CD4 cell count last recorded (112.8 cells/µL vs. 92.0 cells/µL, p-
value: 0.045) and at ART initiation (84.0 cells/µL vs. 73.2 cells/µL, p-value: 0.06) were higher 
for patients in sites with primarily active screening entry points (See Table 11, “Results – 
Sensitivity Analyses”, Appendix A for more information). The median difference in months 
between the date of last recorded CD4 and last scheduled visit was similar for patients in sites 
with mainly active and non-active screening entry points (2.4 months vs. 2.6 months).  Lastly, 
assuming that patients lost to follow-up within the first year from Active Screening Entry Point 





of 0.27 (95% CI: 0.24-0.29) when the final model was refitted. Conversely, assuming that the 
former died while the latter patients survived led to a hazard ratio of 3.25 (95% CI: 2.28-4.63) 







The results show that the rate of death for patients in sites with primarily active screening 
entry points (e.g. Provider Initiated Testing and Counseling, Prevention of Mother-to-Child 
Transmission) is not statistically different than that of patients in sites with primarily non-active 
screening entry points (e.g. In or Outpatient Wards, Tuberculosis clinics).  Several factors 
including lack of adherence to ART, programmatic-related delays in ART initiation, and/or low 
CD4 cell count at ART initiation may explain the findings.  ART adherence is the most 
important predictor of survival once treatment is initiated [127].  Any survival advantage gained 
by an earlier diagnosis would be diminished by poor adherence.  Though not measured in our 
study, the existing literature shows respectable levels of adherence for patients in these settings 
[134].  In addition, the Cox models were adjusted for site patient-provider ratio and site type 
which can influence ART adherence indirectly.  Lastly, all of the sites offered ART adherence 
support at and after ART initiation.  Thus, even though we cannot rule out adherence as a factor, 
we have no evidence to suspect there was a significant difference in ART adherence between the 
comparison groups.   
Programmatic-delays in ART initiation can diminish any survival advantage gained from 
an earlier diagnosis due to active screening.  Though patients in sites with active screening entry 
point started ART generally 13 days earlier than those in sites with non-active screening entry 
points, this difference was not statistically significant and adjusting for it did not materially 
change study results.  The most likely factor explaining our findings is the low patient CD4 cell 
count at ART initiation.  CD4 cell count at ART initiation is a well-established predictor of 
survival [5, 8, 127].  The mean CD4 cell count at ART initiation for patients in sites with active 





cells/μL) World Health Organization’s threshold for ART initiation  [41, 43, 44].  Thus, even in 
the best case scenario patients in our study population typically started ART at advanced stages 
of the infection and as a result were at an increased risk of death.  
 It is worth noting that despite the challenging circumstances under which active screening 
was implemented, the results are in the expected direction [HR (95% CI): 0.82 (0.64 – 1.06)].  
HIV-positive individuals in resource-limited settings face multiple challenges which hinder HIV 
testing (provider or patient-initiated) and linkage to the treatment cascade resulting in increased 
risk of death [1, 65, 97, 100, 135].  In addition, most healthcare systems in low- and middle-
income countries are in a weak state and are poorly integrated.  These conditions limit the 
opportunities for provider to interact with patients and prescribe an HIV test before the infection 
has progressed to AIDS. In those instances where people living with HIV have been diagnosed 
early in the infection, structural barriers may impede timely ART initiation thus hampering the 
potential benefits of active screening on survival [14, 91].   
 To our knowledge this is the first study testing the association between active screening 
at the clinic level and survival.  Most studies on active screening have focused primarily on the 
acceptability of provider-initiated testing, and the rate of identification of previously 
undiagnosed people living with HIV [11, 50, 136].  Thus, we cannot compare our main findings. 
However, similar to other studies the mean patient CD4 cell count at ART initiation was low 
independent of potential exposure to active screening [49, 99, 120].     
There are some study limitations.  The classification of entry points as active or non-
active screening was based on how HIV related services operated historically and not on survey 
data.  Nonetheless, for entry points such as Provider Initiated Testing and Counseling and 





characteristic of these programs while for others, such as TB clinics, it was not the norm at the 
time of this study and therefore misclassification in an unlikely contributing factor.  Four of the 
seven NASEP sites included an active screening entry point (three had Provider Initiated Testing 
and Counseling, and one had Prevention of Mother-to-Child Transmission) paired with a non-
active screening entry point.  This likely contributed to underestimation of the protective effect 
of active screening since it made non-Active Screening Entry Point sites more similar to Active 
Screening Entry Point sites.  The programmatic and site level data collected through the IeDEA 
Site Assessment Tool reflects information at one point in time which may not reflect conditions 
present during the entire follow-up period, thus potentially limiting our ability to fully adjust for 
potential confounders.   
A considerable amount of the study patient population was lost to follow-up. Studies 
have shown that ART patients lost to follow-up, especially shortly after ART initiation, have 
higher probabilities of death which result in an overestimation of survival rates [137-140].  The 
sensitivity analysis showed no statistically significant difference in the proportion of patients lost 
to follow-up or recorded as dead within one year of ART initiation between active and non-
active screening sites.  Therefore, it is unlikely that patient attrition biased study results. 
However, if a bias was introduced due to attrition it may bias the study results towards the null 
since patients lost to follow-up from active screening sites had higher mean CD4 cell count at 
ART initiation (+11 cells/μL) and at last follow-up (+21 cells/μL). As shown in our analysis, if 
we were to assume that all patients lost to follow-up from Active Screening Entry-Point sites 
survived while all those from non-Active Screening Entry Point sites died (or vice-versa), the 
results, (HR: 0.27; 95% CI: 0.24-0.29; or vice versa HR: 3.25; 95% CI: 2.28-4.63) would be 





unknown whether attrition can bias our findings since studies in this area have not investigated 
its impact on programmatic level factors [137, 139, 140].  We will further investigate this issue 
in future analyses.   
This study has several strengths.  To our knowledge, this is the first study investigating 
the relationship between active screening at the clinic level and survival.  The dataset has a 
substantial number of sites each with a considerable number of ART patients.  The sites were 
from diverse geographic settings and data collection extended over several years.  The 
completeness of the data was high for all the variables included in the final model.  The multi-
level models were adjusted for individual, programmatic and contextual variables which is 
uncommon in these types of studies.  Finally, given the nature of the data collection the results 
represent real world conditions and thus account for barriers to HIV testing and ART initiation 
operating in these settings. The results are likely generalizable to resource-limited settings with 







       AIDS remains one of the main causes of premature mortality in low- and middle-
income countries mainly because of lack of knowledge of HIV status and late ART initiation [1, 
12, 15, 35].  Active screening for HIV has been promoted and adopted as a strategy to identify 
and treat HIV-positive individuals during the early stages of the infection [16, 131]. Our findings 
failed to demonstrate a statistically significant advantage in survival for patients is sites with 
primarily active screening entry points. The association, however, is in the expected direction. 
Independent of these findings, the demonstrated benefits of active screening (e.g. high 
acceptability, increased number of patients tested and higher rate of identification of previously 
undiagnosed people living with HIV) support adoption of this intervention particularly in regions 
with a high HIV burden and where a low proportion of the population is unaware of their HIV 
status.  To become effective in improving survival, the implementation of active screening 
programs in low- and middle-income countries may require a systematic shift to a more 
preventative approach to healthcare and improved referral mechanism to efficiently bring those 
in need into treatment. This will increase the opportunities for practitioners to identify HIV-


























Tables and Figures 





Table 1. Distribution, Key Demographic and Outcome Statistics of Patients Initiating 
Antiretroviral Treatment 2003 to 2008 in the 29 Sites in East Africa.  
                  
         No. (% or Min-Max) 
     
Patient Population by Country 
  Kenya        33,586 (74.1) 
  Uganda        9,737   (21.5) 
  Tanzania        2,018   (4.4) 
 
Patient Population by Site Type 
  Health Center/Clinic       9,539   (21.0) 
  District/Provincial Hospital      17,244 (38.0) 
  Teaching/National Referral Hospital    18,558 (40.9) 
 
Patient by Year of ART Initiation 
  2003         689      (1.5) 
  2004         3,012   (6.6) 
  2005         9,169   (20.2) 
  2006         10,931 (24.1) 
  2007         12,776 (28.2) 
  2008         8,764   (19.3) 
 
Median Age at ART Initiation     37  (18-88) 
 
Female Patients       29,118  (64.3) 
 
Median Survival Time (months)     14.2   (0-75.6) 
 
Total person-time of observation (months)    809,860    
 
Documented Deaths       3,082  (6.8) 
 









Table 2. Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
     
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent 
(N=29) Country Site Type  Served  (N=47,518) Initiation ART Initiation Female 
     
EA01  Kenya  District/  In-between 3993  2003-2008 36 (18-88)  66.0 
    Provincial Hospital Urban/rural  
 
EA02  Kenya  Health Center/Clinic Mainly  172  2007-2008 35 (20-69)  62.9 
       Urban 
 
EA03  Kenya  Health Center/Clinic Mainly  94  2007-2008 29 (19-49)  100.0 
       Urban 
 
EA04  Kenya  Teaching/  Mainly  8592  2003-2008 37 (18-81)  58.7 
    National Referral  Urban 
Hospital 
 
EA05  Kenya  District/Provincial In-between 324  2005-2008 39 (19-70)  73.2  
    Hospital  Urban/rural 
 
EA06  Kenya  District/Provincial In-between 583  2006-2008 38 (20-75)  66.6  
    Hospital  Urban/rural 
 
EA07  Kenya  District/Provincial In-between 322  2006-2008 38 (19-61)  66.2  
    Hospital  Urban/rural 
 
EA08  Kenya  District/Provincial In-between 788  2004-2008 37 (19-79)  65.5  
    Hospital  Urban/rural 
 
 








Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
        
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent 
(N=29) Country Site Type  Served  (N=47,518) Initiation ART Initiation Female 
     
EA09  Kenya  District/Provincial Mainly  2023  2004-2008 38 (18-74)  70.0   
    Hospital  Urban 
 
EA10  Kenya  Health Center/Clinic Mainly  891  2007-2008 38 (20-78)  65.5 
       Rural 
 
EA11  Kenya  Health Center/Clinic In-between 2004  2004-2008 38 (18-75)  65.1 
       Urban/rural 
 
EA12  Kenya  Health Center/Clinic Mainly  788  2004-2008 38 (19-77)  62.4 
       Rural 
 
EA13  Kenya  District/Provincial Mainly  2443  2006-2008 37 (18-81)  64.5  
    Hospital  Urban 
 
EA14  Kenya  District/Provincial Mainly  142  2007-2008 35 (20-62)  64.1  
    Hospital  Urban 
 
EA15  Kenya  Health Center/Clinic In-between 1343  2004-2008 37 (19-76)  66.8 
       Urban/rural 
 
EA16  Kenya  Health Center/Clinic Mainly  2781  2003-2008 38 (18-76)  64.7 












Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
        
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent 
(N=29) Country Site Type  Served  (N=47,518) Initiation ART Initiation Female 
     
EA17  Kenya  District/Provincial Mainly  2933  2005-2008 38 (18-80)  68.1  
    Hospital  Urban 
 
EA18  Kenya  District/Provincial In-between 538  2005-2008 36 (19-77)  62.5  
    Hospital  Urban/rural 
 
EA19  Kenya  Health Center/Clinic Mainly  782  2007-2008 33 (18-72)  66.8 
       Urban 
 
EA20  Kenya  Health Center/Clinic Mainly  55  2007-2008 21 (18-25)  77.1 
       Urban 
 
EA21  Kenya  District/Provincial In-between 1080  2006-2008 36 (18-77)  62.6  
    Hospital  Urban/rural 
 
EA22  Kenya  Health Center/Clinic Mainly  629  2004-2008 38 (18-78)  68.8 
       Rural 
 
EA23  Kenya  District/Provincial Mainly  286  2003-2008 30 (18-57)  73.4  
    Hospital  Urban 
 
EA27  Tanzania Teaching/National Mainly  607  2005-2008 40 (18-82)  61.0  
    Referral Hospital Urban 
 
 









Table 2 (Cont’d). Key Characteristics of the 29 Sites in East Africa and Attributes of their Respective Patient Population. 
      
         ǂNo. of ART 
Site        Population Patients Year of ART Median Age at Percent 
(N=29) Country Site Type  Served  (N=47,518) Initiation ART Initiation Female 
     
EA28  Tanzania District/Provincial Mainly  1411  2005-2008 38 (19-82)  65.4 
    Hospital  Urban 
 
EA30  Uganda Teaching/National Mainly  339  2003-2008 32 (18-52)  69.6  
    Referral Hospital Urban 
 
EA32  Uganda Teaching/National Mainly  1363  2007-2008 35 (18-80)  60.5  
    Referral Hospital Rural 
 
EA33  Uganda District/Provincial Mainly  378  2003-2008 32 (19-71)  68.8  
    Hospital  Urban 
 
EA34  Uganda Teaching/National Mainly  7657  2003-2008 36 (18-80)  64.2  
    Referral Hospital Urban 
 
















Table 3. Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.            
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA01 Provider Initiated Testing and Voluntary Counseling and   Yes 
  Counseling    Testing (directly) 
 
EA02  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (via Referral)   Testing (directly)/Other  
       (Transfer In) [tied] 
 
EA03  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (directly) and    Counseling 
   (via Referral)[tied] 
 
EA04  Provider Initiated Testing and Inpatient Wards    No 
  Counseling 
 
EA05  Provider Initiated Testing and Prevention of Mother to Child  Yes 
  Counseling    Transmission Program within  
the Antenatal Clinic 
 
EA06  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral) 
 
EA07  Inpatient Wards   Provider Initiated Testing and  No 
Counseling 
 
EA08  Voluntary Counseling and  Provider Initiated Testing and  Yes 








Table 3 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA09  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
the Antenatal Clinic 
 
EA10  Voluntary Counseling   Provider Initiated Testing and  Yes 
  and Testing (directly)   Counseling 
 
EA11  Prevention of Mother to Child Voluntary Counseling and   Yes 
  Transmission Program within  Testing (directly) 
  the Antenatal Clinic 
 
EA12  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (via Referral)   Counseling 
 
EA13  Voluntary Counseling and  Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral) 
 
EA14 Voluntary Counseling and  Tied between Provider Initiated  
Testing (directly)   Testing and Counseling and TB  Yes     
Clinic followed by Voluntary  
Counseling and Testing (directly) 
 
EA15  Provider Initiated Testing  TB Clinic     No 









Table 3 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA16  Provider Initiated Testing  Voluntary Counseling and   Yes 
  and Counseling   Testing (directly) 
 
EA17  Provider Initiated Testing  Prevention of Mother to Child  Yes 
  and Counseling   Transmission Program within  
       the Antenatal Clinic 
 
EA18  Inpatient Wards   Voluntary Counseling and   No 
       Testing (directly) 
 
EA19  Voluntary Counseling and   Voluntary Counseling and   Yes 
  Testing (directly)   Testing (via Referral)/ 
       Other (Research)[tied] 
 
EA20  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 
EA21  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 









Table 3 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA23  Voluntary Counseling and  Provider Initiated Testing and  Yes 
  Testing (directly)   Counseling 
 
EA27  Provider Initiated Testing  Prevention of Mother to Child  Yes 
  and Counseling   Transmission Program within  
       the Antenatal Clinic 
 
EA28  Voluntary Counseling and  Prevention of Mother to Child  Yes 
  Testing (directly)   Transmission Program within  
       the Antenatal Clinic 
 
EA30  Prevention of Mother to Child Voluntary Counseling and   Yes 
  Transmission Program within  Testing (directly) 
  the Antenatal Clinic 
 
EA32  Voluntary Counseling and  Outpatient Ward    No 
  Testing (directly) 
 
EA33  Provider Initiated Testing and Voluntary Counseling and    Yes 
Counseling     Testing (directly)/Prevention of Mother 
to Child Transmission Program within  










Table 3 (Cont’d). Classification of the 29 Sites by Active Screening Entry Points based on Primary and Secondary Source of Patients.           
Site            Site has Primarily    
(N=29) Primary Source of Patients  Secondary Source of Patients  Active Screening Entry Points 
 
EA34  Prevention of Mother to Child Inpatient Wards    No 
  Transmission Program within 






 Figure 1.  Crude Kaplan-Me+ier Survival Curves Comparing Patients in Active Screening Entry 










Table 4. Distribution of Potential Confounders and Associations with Active Screening Entry Points (Exposure) and Patient Survival 
(Outcome). 
 
Sites with  Sites without  Association with Association with  
Active Screening Active Screening the Exposure  the Outcome  
Entry Points  Entry Points     
N (%)   N (%)   OR (P-value1)  HR (P-value) 
 
Patient-level Characteristics 
Number of Patients     24,725 (100)  20,616 (100)  --   -- 
Male Sex     8,348 (33.8)  7,845 (38.1)  0.84 (<0.09)  1.54 (<0.0001) 
 
Site and Programmatic-level 
Level Characteristics 
Number of Sites    21 (100)  8 (100)  --   -- 
Sites by Type 
Health Center/Clinic   7 (33.3)  3 (37.5)  0.39 (0.61)  1.05 (0.78) 
District/Provincial Hospital  12 (57.1)  2 (25)   Reference  Reference 
Teaching/National Referral   2 (9.5)   3 (37.5)  0.11 (0.08)  0.64 (0.0002) 
Hospital 
 
Site Patient-Provider Ratio 
0.0 to 4.0    5 (23.8)  1 (12.5)  1.67 (1.00)  0.34 (<0.0001) 
4.01 to 8.5    5 (23.8)  3 (37.5)  0.56 (1.00)  0.86 (0.57) 
8.6 to 11.99    6 (28.6)  2 (25)   Reference  Reference 
12.0 to 35.53    5 (23.8)  2 (25)   0.83 (1.00)  0.77 (0.13) 
 












Table 4 (Cont’d). Distribution of Potential Confounders and Associations with Active Screening Entry Points (Exposure) and Patient 
Survival (Outcome). 
 
Sites with  Sites without  Association with Association with  
Active Screening Active Screening the Exposure  the Outcome  
Entry Points  Entry Points     
N (%)   N (%)   OR (P-value1)  HR (P-value) 
 
Patient Population Served Predominantly 
Urban Patients   13 (61.9)  3 (37.5)  Reference  Reference 
Rural Patients    2 (9.5)   2 (25)   0.23 (0.25)  1.65 (0.05) 
In between Urban/Rural  6 (28.6)  3 (37.5)  0.46 (0.63)  1.59 (0.0001) 
 
Site’s ART Eligibility Criterion for  16 (76.2)  5 (62.5)  1.92 (0.65)  1.42 (0.03)  
Patients in WHO Clinical Stage 1 or 2  
(<200 vs 200+ cells/µL)    
 





















Table 5. Hazard Ratios (HR) and 95% Confidence Intervals for Active Screening Entry-Point (ASEP) Cox Models: 1) Crude Model,  
2) Patient Factors Only Adjusted Model, 3) Programmatic Factors Only Adjusted Model, and 4) Patient and Programmatic Factors 
Adjusted Models (with and without “presence of a waiting list”).  
                  
Model 1: Crude Model 2: Adj. for Model 3: Adj. for Model 4: Adj. for Model 5: Adj.  
    HR (95% CI)  for Patient  Programmatic  for Patient and  for Patient and  
  Factors  Factors  Programmatic  Programmatic 
HR (95% CI)  HR (95% CI)  Factors  Factors  
Parameter            HR (95% CI)  HR (95% CI) 
           
Active Screening  1.32   1.35   0.83   0.83   0.82   
Entry Points   (1.03-1.70)  (1.04-1.75)  (0.65-1.07)  (0.63-1.09)  (0.64-1.06) 
(Yes vs. No)  
     
Sex    ---   1.56   ---   1.58   1.58 
(Male vs Female)     (1.43-1.71)     (1.46- 1.71)  (1.46-1.71) 
  
Sites by Type 
Health Center/Clinic ---   ---   1.02   0.99   1.02  
vs District/Provincial       (0.78-1.33)  (0.76-1.29)  (0.78-1.33) 
Hospitals 
 
Teaching/National ---   ---   0.54   0.51   0.51   




Site Patient-Provider Ratio  
0-4.0 vs 8.6-11.99 ---   ---   0.42   0.35   0.40 
          (0.27-0.67)  (0.23- 0.53)  (0.25-0.64)  
 
 4.01-8.5 vs 8.6-11.99 ---   ---   0.98   0.96   0.99 








Table 5 (Cont’d). Hazard Ratios (HR) and 95% Confidence Intervals for Active Screening Entry-Point (ASEP) Cox Models: 1) Crude 
Model, 2) Patient Factors Only Adjusted Model, 3) Programmatic Factors Only Adjusted Model, and 4) Patient and Programmatic 
Factors Adjusted Models (with and without “presence of a waiting list”).  
                  
Model 1: Crude Model 2: Adj. for Model 3: Adj. for Model 4: Adj. for Model 5: Adj.  
    HR (95% CI)  for Patient  Programmatic  for Patient and  for Patient and  
       Factors  Factors  Programmatic  Programmatic 
HR (95% CI)  HR (95% CI)  Factors  Factors 
Parameter            HR (95% CI)  HR (95% CI)  
 
Site Patient-Provider Ratio  
12-35.33 vs 8.6-11.99 ---   ---   1.13   1.09   1.14 
          (0.84-1.52)  (0.83- 1.45)  (0.84-1.53)   
 
Patient Waiting List  ---   ---   1.23   ---   1.24    
(Yes vs No)         (0.78-1.95)     (0.77-1.97) 
 
Predominant Patient   
Population Served   
Rural vs Urban  ---   ---   1.48   1.46   1.47   
          (0.98-2.22)  (0.96- 2.21)  (0.97-2.22)   
In Between Urban/Rural 
vs Urban  ---   ---   1.24   1.21   1.23 
          (0.89-1.71)  (0.88- 1.67)  (0.89-1.71) 
 
Site’s ART Eligibility  ---   ---   1.10   0.88   1.08 
Criterion for Patients in       (0.67-1.81)  (0.71-1.10)  (0.65-1.79) 
WHO Clinical Stage  











Figure 2. Adjusted Survival Curves Comparing Patients in Active Screening Entry Points Sites (blue) with Patients in Non- 






Table 6. Crude Association Between the Exposure (Active Screening Entry Points (ASEP)) and 
the Potential Mediator (CD4 Cell Count at ART initiation) and the Potential Mediator (CD4 Cell 
Count at ART Initiation) and Outcome (Patient Survival). 
 
Mean CD4 at     
ART Initiation  P-Value 
 
Association Between Exposure and Mediator 
Active Screening Entry Point Sites   104.57    Reference 
Non-Active Screening Entry Point Sites  84.93    0.03 
 
       HR    P-Value 
Association Between Mediator and Outcome 
LogCD4 (all sites)     0.64    <0.0001 
LogCD41 (ASEP sites only)    0.64    <0.0001 
LogCD41 (non-ASEP sites only)   0.63    <0.0001  
 
1CD4 is modeled with a time-dependent covariate (logCD4*survival) to meet the proportional 
hazard assumption. HR accounts for this covariate. 






















 Table 7. Test for Mediation by CD4 Cell Count at ART Initiation Using Final Active Screening Entry Point Model (Model 5).   
 
Model 5 (Final Model)   Model 5 with Potential Mediator  
Beta Estimate      Beta Estimate   
Parameter      HR (95% CI)     HR (95% CI)  
Active Screening Entry Points  -0.19605     -0.06916   
(Yes vs. No)     0.82 (0.64-1.06)    0.93 (0.75-1.16) 
 
Sex      0.45580     0.33020    
(Male vs Female)    1.58 (1.46-1.71)    1.39 (1.25-1.55) 
 
Sites by Type 
Health Center/Clinic vs  0.02041      -0.08532   
District/Provincial Hospitals  1.02 (0.78-1.33)    0.92 (0.70-1.21) 
 
Teaching/National Referral  -0.67071     -0.55723  
Hospital vs District/Provincial 0.51 (0.32-0.80)    0.57 (0.39-0.84) 
Hospitals 
 
Site Patient-Provider Ratio  
 0-4.0 vs 8.6-11.99   -0.91727      -0.68753   
      0.40 (0.25-0.64)    0.50 (0.32-0.82) 
 
 4.01-8.5 vs 8.6-11.99   -0.01561      0.11059   
      0.99 (0.69-1.41)    1.12 (0.82-1.53) 
 
 12-35.33 vs 8.6-11.99   0.12785      0.06884   









Table 7 (Cont’d). Test for Mediation by CD4 Cell Count at ART Initiation Using Final Active Screening Entry Point Model  
(Model 5). 
 
Model 5 (Final Model)   Model 5 with Potential Mediator  
Beta Estimate      Beta Estimate   
Parameter      HR (95% CI)     HR (95% CI)  
Patient Waiting List     0.21201      0.12268   
(Yes vs No)     1.24 (0.77-1.97)    1.13 (0.73-1.76) 
 
Predominant Patient Population Served  
 Rural vs Urban   0.38651     0.48977   
      1.47 (0.97-2.22)    1.63 (1.14-2.34) 
 
In Between Urban/   0.20696      0.23415   
 Rural vs Urban   1.23 (0.89-1.71)    1.26 (0.93-1.73) 
 
Site’s ART Eligibility Criterion  0.07417      0.17030  
for Patients in WHO Clinical Stage  1.08 (0.65-1.79)    1.19 (0.74-1.90) 
1 or 2 (<200 vs 200+ cells/µL) 
 
Age (years) 
 18-23 vs. 30-35   ---      0.18803   
            1.21 (0.84-1.73) 
 
24-29 vs. 30-35   ---      0.01926  
            1.02 (0.91-1.15) 
 36-41 vs. 30-35   ---      -0.01075   
            0.99 (0.88-1.11) 
 
42-47 vs. 30-35   ---      0.05409   








Table 7 (Cont’d). Test for Mediation by CD4 Cell Count at ART Initiation Using Final Active Screening Entry Point Model  
(Model 5).  
 
Model 5 (Final Model)   Model 5 with Potential Mediator  
Beta Estimate      Beta Estimate   
Parameter     HR (95% CI)     HR (95% CI)  
Age (years) 
   
 48-53 vs. 30-35   ---      0.19145   
            1.21 (1.07-1.37)  
 
54-59 vs. 30-35   ---      0.17452   
1.19 (0.99-1.43) 
  
60-65 vs. 30-35   ---      0.24358  
1.28 (0.96-1.69) 
  
66-88 vs. 30-35   ---      0.58152  
1.79 (1.30-2.48) 
 





1LogCD4: potential mediator; modeled as a time dependent variable to meet  
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 The central aims of this dissertation were to: 
1) critically review and synthesize the literature examining individual-, programmatic-, 
and societal-level barriers to HIV testing, enrollment into pre-ART care, and ART 
initiation;  
2) examine the association between patient CD4 cell count at ART initiation and the 
conduct of active screening at HIV/AIDS care and treatment sites; 
3) examine the association between patient CD4 cell count at ART initiation and sites 
with primarily active screening entry points; 
4) examine the association between patient survival and sites with primarily active 
screening entry points; 
5) examine patient CD4 cell count at ART initiation as a mediator of the association 
between patient survival and active screening entry points. 
Summary of Results 
 In Chapter 2, I conducted a critical review of the literature to identify barriers to ART 
initiation along the HIV treatment cascade.  The findings identified: 
  1) individual, programmatic and societal-level barriers to HIV testing, enrolling into 
 care, and ART initiation; 
  2) barriers pertaining to lack of knowledge of HIV/AIDS and ART (e.g. HIV/AIDS 
 symptomatology, ART benefits, ART toxicity), limited accessibility to services, poor 






 In Chapter 3, I performed separate analyses to tests the association between the exposures 
“Active Screening” and “Active Screening Entry Points” with the outcome patient CD4 cell 
count at ART initiation.  The result showed that patients in sites with predominantly “Active 
Screening Entry Points” initiate ART, on average, with CD4 cell counts 24 cells/µL higher than 
patients in sites with mainly “non-Active Screening Entry Points.”  The analyses in Chapter 4, 
assessed the relationship between “Active Screening Entry Points” and survival, and whether this 
relationship was mediated by patient CD4 cell count at ART initiation.  The findings failed to 
show a statistically significant difference in survival between patients in sites with and without 
“Active Screening Entry Points” [HR (95% CI): 0.82 (0.64 – 1.06)] though the association was 
in the expected direction.      
 Key Strengths and Limitations 
 This dissertation has some limitations. Given the nature of qualitative studies, we cannot 
determine the extent to which the barriers identified hinder progression through the stages of the 
treatment cascade.  Though results from quantitative studies can help shed light on this matter, 
the ones identified were cross-sectional in nature and thus should be interpreted with caution.   
The classification of entry points as active or non-active screening was based on how 
these HIV related services have operated historically and not based on a detailed response on a 
survey.  Nonetheless, for entry points such as Provider Initiated Testing and Counseling and 
Prevention of Mother-to-Child Transmission active screening has always been a defining 
characteristic of these programs while for others, such as TB clinics, it was not the norm at the 
time of this study.  Lastly, the programmatic and site level data collected through the IeDEA Site 
Assessment Tool reflects information at one point in time which may not be indicative of 





 There are several strengths to the studies in this dissertation.  The articles identified in the 
literature review covered the four different regions which carry the biggest burden of the HIV 
epidemic. Studies from sub-Saharan Africa, the region with the highest HIV-prevalence, and 
South Africa, the country with the largest number of people living with HIV, were well-
represented.  The years of publication of the articles (2001 to 2012) coincide with the period 
when major scale-up of ART occurred in low- and middle-income countries.  To my knowledge, 
we present the first study investigating the relationship between active screening and survival.  
The dataset has a respectable number of sites each with a considerable number of ART patients.  
The sites were from diverse geographic settings and data collection extended over several years.  
Patient, programmatic and contextual level variables were considered for statistical adjustment.  






Public Health Relevance 
We have yet to reach the point when we can recognize the accomplishments of ART 
scale-up without strongly emphasizing remaining challenges.  The initiation of treatment in the 
advanced stages of the infection is a major factor undermining the global efforts on the HIV 
epidemic [15].  Late ART initiation is more of a reflection of the deficiencies in providing 
healthcare to populations in low- and middle-income countries than an individual’s 
determination to access ART at the appropriate time. 
The HIV epidemic has shone a spotlight on the neglected healthcare systems of low- and 
middle-income countries.  This neglect is reflected by the observation that most of the identified 
barriers to ART initiation are somehow related to lack of continuity, affordable, good quality 
healthcare.  Chronic conditions like HIV require continuous testing of those without the virus as 
well uninterrupted monitoring of those with the virus.  Therefore, unless the limitations of the 
healthcare system are considered, interventions addressing late ART initiation will be 
undermined.  This may be the case for active screening as a means to combat late ART initiation. 
Although the results in Chapters 3 show a CD4 cell count advantage for patients in 
“Active Screening Entry-Points”, the mean CD4 cell count of these patients are well-below all of 
the World Health Organization ART guidelines underlining both the severity and complexity of 
late ART initiation in these settings [41, 43, 44, 53].  Given that most patients in the study 
population started treatment at advanced stages of the infection, it is not surprising that a 
considerable difference in survival was not detected.  These results are likely a reflection of the 
failure of the healthcare system rather than active screening. If there is limited or no contact 





opportunity to initiate testing during this critical period even if they are fully compliant with 
active screening. 
 It is unlikely that the limitations of healthcare systems in low- and middle-income 
countries will be addressed in the upcoming decades.  This reality should encourage public 
health institutions to promote comprehensive, multifaceted interventions which consider the 
context in which they are to be applied.  The fact that under real world condition the results show 
that active screening leads to a moderate increase in CD4 cell count at ART initiation is 
promising. In addition, the demonstrated benefits of active screening (e.g. high acceptability, 
increased number of patients tested and higher rate of identification of previously undiagnosed 
people living with HIV) merit adoption of this intervention particularly in regions with a high 
HIV burden and where a low proportion of the population is aware of their HIV status.  To 
become effective in improving survival, the implementation of active screening programs in low- 
and middle-income countries may require a systematic shift to a more preventative approach to 
healthcare with improved referral mechanism to efficiently bring those in need into treatment. 
This will increase the opportunities for practitioners to identify HIV-positive individuals earlier 
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 Methodological Details: Chapter 2 (Literature Review: Barriers to ART Initiation) 
Search Strategy 
 PubMed, Eric and Popline were considered but not included in this review.  PubMed 
would have provided the same information as Ovid Medline but only on a different interface.  
The focus of Eric and Popline databases, education and international reproductive health, 
respectively, are not directly in line with the focus of this search. 
 




 The patient date of enrollment and the date active screening was initiated at the site were 
used to calculate the percentage of patients who enrolled into care after active screening 
commenced.  When the day and/or month were missing from the start date of active screening, 
the middle of the month (15) and year (June) were used to complement the year.  Among 27 sites 
reporting information on active screening, none reported the day and 17 did not report the month 
for the date active screening began.  Patients enrolling into care at least one day following the 
start of active screening were counted in the proportion of who enrolled after active screening 
began.    
Potential Confounders: 
Patient-level Variables 
Following the assessment for linearity (see below for details), age at ART initiation was 
operationalized as a set of equally spaced indicator variables of five-year intervals ranging from 





education level achieved, availability of electricity and piped water in the home, monthly 
income) could not be considered for statistical adjustment due to the high proportion of missing 
values.      
Programmatic-level Variables 
ART Eligibility Criteria 
The sites’ CD4 cell count criterion for ART initiation at each WHO stage was analyzed 
using a set of three indicator dichotomous variables: 1) for WHO clinical stages 1 and 2, sites 
using a CD4 count threshold of less than 200 cells/µL to initiate ART for patients with this 
clinical stage were compared with those using CD4 counts of 200 cells/µL or more; 2) for WHO 
clinical stage 3, sites using a CD4 count threshold of less than 350 cells/µL to initiate ART for 
patients with this clinical stage were compared with those using CD4 counts of 350 cells/µL or 
more; 3) for WHO clinical stage 4, sites using a CD4 count threshold of less than 250 cells/µL to 
initiate ART for patients with this clinical stage were compared with those using CD4 counts of 
250 cells/µL or more. 
Patient-provider ratio  
Patient-provider ratio was calculated for each site as the total number of patients on ART 
during the first quarter of 2008 divided by the total number of days providers are available. The 
first quarter of 2008 was chosen because it was the time closest to when 1) the provider 
information was collected and 2) all the sites had patients on ART.  Note that category 12-35.53 
was made considerably wider compared with the other three (ratios 0-4.0, 4.01-8.5, 8.6-11.99) to 
include the outlier value of 35.52; otherwise the range would have only extended to 18.54.  





with an equal number of sites of similar patient-provider ratios to minimize residual confounding 
[141].   
Fees for Services, ARV Stockouts, Frequency of CD4 Cell Monitoring  
Since there was virtually no variability in the responses, the following constructs were 
not considered for statistical adjustment: charging fees for services rendered (laboratory tests, 
first line ART, opportunistic infection prophylaxis, opportunistic infection treatment, routine 
follow-up care, and transportation to the clinic), experiencing ARV disruptions, frequency of 
CD4 cell count monitoring.   
Site-level Variables 
Site Classification 
Sites were also classified as private or public.  Due to a small number of private sites, this 
variable was not considered for statistical adjustment. 
Statistical Analysis 
Justification for the Use of Mixed Linear Regression Models and Assessment of Statistical 
Assumptions 
Due to the subject matter of this dissertation (an infectious disease that tends to cluster in 
space and time), and the substantial grouping of patients into sites (up to 8,500 in one of the 
sites) it is likely that the degree of clustering leads to underestimated standard errors 
necessitating the need for regression models, such as random effects models, that take clustering 
into account. In addition to the latter points, I also calculated the intraclass correlation (ICC) by 
fitting an unconditional means model to assess the degree of clustering.  The statistical 





where g=the number of groups and k=the number of subjects in each group [142].  The average 
number of subjects per site was 1,563 with a minimum per site of 54.      
The estimated ICC was 0.035 [0.05207/(1.4175+0.05207)] with an AIC of 120766.3.  
Even when k=54, the p-value for F-statistic 2.96 [1+53(0.035)/(1-0.035)] with degrees of 
freedom 28 and 1,537 (29*53) is less than 0.05.  The AIC for the unconditional model without 
the random intercept is 120933.5. Given the size and statistical significance of the ICC, the large 
number of subjects per cluster (range: 55 to 8,592), that infectious diseases like HIV tend to 
cluster in space and time, and the view by some statisticians that when the number of subjects in 
a group is large even ICC less than 0.1 can influence significance tests [142], the clustering in 
the data could not be ignored. Mixed models with random intercepts were fitted to account for 
the clustering [118] though Generalized Estimating Equation models also would have been 
appropriate.        
The linearity assumption for continuous variables patient-provide ratio and age at ART 
initiation was assessed separately for each variable using two approaches.  We fitted a model 
with both a continuous and a squared-term version of the covariate and tested the statistical 
significance (using alpha = 0.05) of the squared-terms.  Secondly, we fitted a bivariable Cox 
model of the outcome and covariate.  Patient-provider ratio was modeled using three indicator 
variables for the four categories created for this variable (0-4.0, 4.01-8.5, 8.6-11.99 (reference 
group), and 12-35.53), and age at ART initiation using eight indicator variables of five-year 
increments for the nine categories (18-23; 24-29; 30-35 (reference group)…66-88).  The 
estimated beta estimates for the indicator variables were plotted and assessed for evidence of a 
linear pattern.  Based on the results of these assessments, patient-provider ratio and age at ART 





model assumptions including normality and homogeneity of variance of the level-1 and level-2 
errors were assessed using the macro “Mixed_DX” [143].  Outside the violation of normality, 
which was addressed through a log transformation of the patient CD4 cell count at ART 
initiation, there were no substantial violation of homogeneity of variance for the level-1 or level-
2 errors.    
Results 
Table 9. Log Scale Estimates for Crude and Adjusted Mixed Models Comparing Patients in Sites 
with and without Active Screening. 
            
Model 1: Crude  Model 2: Adjusted 
Parameter     Mean CD4 (P-Value)  Mean CD4 (P-Value) 
 
Intercept     4.5923 (<0.0001)  4.5592 (<0.0001) 
 
Active Screening     0.01058 (0.91)  -0.03055 (0.76) 
(Active vs Non-Active) 
 
Site Patient- Provider Ratio 
(0-4.0 vs 8.6-11.99)   ---    0.3000 (0.11) 
(4.01-8.5 vs 8.6-11.99)  ---    0.2251 (0.07) 
(12-35.33 vs 8.6-11.99)  ---    -0.02364 (0.84) 
 
Site’s ART Eligibility Criterion for  ---    -0.06920 (0.61)   
Patients in WHO Clinical Stage 1 or 2  
(<200 vs 200+ cells/µL) 
 
Site’s ART Eligibility Criterion for   ---    -0.02661 (0.84)  
Patients in WHO Clinical Stage 3 











 Table 10. Log Scale Estimates for Crude and Adjusted Mixed Models Comparing Patients in Sites with and without Active Screening 
Entry Points. 
                  
Model 1: Crude Model 2: Adj. for Model 3: Adj. for  Model 4: Adj. for 
     Mean CD4  Patient Factors Programmatic Factors  Patient and  
(P-Value)  Mean CD4  Mean CD4   Programmatic Factors 
        (P-Value)  (P-Value)   Mean CD4 
Parameter               (P-Value) 
     
Intercept    4.4418 (<0.0001) 4.5299 (<0.0001) 4.4648 (<0.0001)  4.5484 (<0.0001) 
  
Active Screening Entry Points 0.2081 (0.03)  0.1911 (0.04)  0.2394 (0.004)  0.2244 (0.005) 
(Active vs. Non-Active)             
 
Sex     ---   -0.2351 (<0.0001)  ---    -0.2349 (<0.0001) 
(Male vs Female)       
 
Site Patient-Provider Ratio  
(0-4.0 vs 8.6-11.99)  ---   ---   0.1630 (0.23)   0.1470 (0.26) 
(4.01-8.5 vs 8.6-11.99) ---   ---   0.2016 (0.03)   0.2032 (0.03) 
 (12-35.33 vs 8.6-11.99) ---   ---   -0.03376 (0.70)  -0.03158 (0.71) 
 
Site’s ART Eligibility Criterion for  ---   ---   -0.1665 (0.11)   -0.1583 (0.12) 
Patients in WHO Clinical Stage 1 or 2  









Table 11. Median time to ART Initiation after Enrolling into Care for Active and non-Active 
Screening Sites. 
 
     Active Screening Non-Active Screening  
Sites   Sites 
 
Median time (days) to   56 (21-140)  56 (19-167) 
ART Initiation (IQR) 
 
 
Table 12. Distribution of WHO Clinical Stage at ART Initiation, Sex and Age at ART Initiation 
for Patients With and Without CD4 Cell Count at ART Initiation. 
 
     Patients With  Patients Without 
     CD4 Cell Count CD4 Cell Count 
     N (%)   N (%) 
 
WHO Stage at ART Initiation: 
   Missing 679 (1.8)  332 (4.4)  
    I 5,909 (15.6)  1,233 (16.5) 
    II 8,005 (21.1)  1,420 (19.0) 
    III 17,335 (45.8)  3,108 (41.6) 
    IV 5,936 (15.7)  1,384 (18.5) 
 
Males     13,607 (36.0)  2,586 (34.6) 
 








Table 13. Comparison of Study Results from the Active Screening Final Model with Results 
Based on Only Kenyan Sites. 
 
 Final Model  Final Model   
 (Study Results) (Kenya Sites Only) 
 Mean CD4  Mean CD4 
Parameter (P-Value)  (P-Value)    
         
Active Screening 
Yes    92.6 (0.76)  107.8 (0.30) 
   No    95.5 (ref)  118.0 (ref) 
 
Site Patient Provider Ratio 
   0-4.0    128.9 (0.11)  137.2 (0.51) 
   4.01-8.5   119.6 (0.07)  123.0 (0.77) 
   8.6-11.99   95.5   (ref)  118.8 (ref) 
   12-35.33   93.3   (0.83)  122.6 (0.75) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 200 cells/µL   89.1 (0.61)  92.2 (0.25) 
   200+  cells/µL   95.5 (ref)  118.8 (ref) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 350 cells/µL   93.0 (0.84)  No Estimates 








Table 14. Comparison of Study Results from the Active Screening Entry Point Final Model with 
Results Based on Only Kenyan Sites. 
 
 Final Model  Final Model   
 (Study Results) (Kenya Sites Only) 
 Mean CD4  Mean CD4 
Parameter    (P-Value)  (P-Value) 
 
Active Screening Entry Points 
 Yes    118.2 (0.005)  138.0 (0.007) 
 No    94.5   (ref)  112.6 (ref) 
 
Sex 
 Male    74.7 (<0.0001) 85.9 (<0.0001) 
 Female   94.5 (ref)  112.6 (ref) 
 
Site Patient Provider Ratio 
 0-4.0    109.4 (0.26)  114.7 (0.92) 
 4.01-8.5   115.8 (0.03)  123.7 (0.28) 
 8.6-11.99   94.5   (ref)  112.6 (ref) 
 12-35.33   91.5   (0.71)  109.8 (0.72) 
 
Site ART Eligibility Criteria for  
Patients in WHO Clinical Stage 1 or 2 
 < 200 cells/µL   80.6 (0.12)  84.9 (0.13) 









Table 15. Comparison of Study Results from the Active Screening Final Model with Results 
Based on 1) Reclassification of “Partial” Sites as “Active Screening” and 2) Exclusion of 
“Partial” Sites. 
 
 Final Model  Final Model  Final Model  
 (Study Results) (Reclassification) (Exclusion) 
 Mean CD4  Mean CD4  Mean CD4 
Parameter    (P-Value)  (P-Value)  (P-Value) 
 
Active Screening 
Yes    92.6 (0.76)  97.50 (0.69)  99.5 (0.29) 
   No    95.5 (ref)  93.6 (ref)  90.0 (ref) 
 
Site Patient Provider Ratio 
   0-4.0    128.9 (0.11)  119.6 (0.19)  106.9 (0.29)  
   4.01-8.5   119.6 (0.07)  117.6 (0.06)  107.0 (0.14) 
   8.6-11.99   95.5   (ref)  93.6 (ref)  90.0 (ref) 
   12-35.33   93.3   (0.83)  88.2 (0.62)  84.3 (0.57) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 200 cells/µL   89.1 (0.61)  87.1 (0.58)  79.6 (0.28) 
   200+ cells/µL   95.5 (ref)  93.6 (ref)  90.0 (ref) 
 
Site ART Eligibility Criteria for Patients 
in WHO Clinical Stage 1 or 2 
   < 350 cells/µL   93.0 (0.84)  92.9 (0.95)  96.7 (0.53) 








Methodological Details: Chapter 4 (Active Screening Entry Points – Patient Survival) 
 
Measures 
Outcome variable:   
For the purpose of our analysis, patients who were lost to follow-up where censored at the 
midpoint between their last recorded visit and the next scheduled visit.   
Potential Confounders: 
Patient-level Variables 
Based on the results of assessment for linearity (see below for details), age at ART 
initiation was operationalized as a set of equally spaced indicator variables of five-year intervals 
ranging from age 18 to 88 years.  Measures of socio-economic status (years of school completed, 
highest education level achieved, availability of electricity and piped water in the home, monthly 
income) could not be considered for statistical adjustment due to the high proportion of missing 
values.      
Programmatic-level Variables 
ART Eligibility Criteria 
The sites’ CD4 cell count criterion for ART initiation at each World Health Organization 
(WHO) stage was analyzed using a set of three indicator dichotomous variables: 1) for WHO 
clinical stages 1 and 2, sites using a CD4 count threshold of less than 200 cells/µL to initiate 
ART for patients with this clinical stage were compared with those using CD4 counts of 200 
cells/µL or more; 2) for WHO clinical stage 3, sites using a CD4 count threshold of less than 350 
cells/µL to initiate ART for patients with this clinical stage were compared with those using CD4 





of less than 250 cells/µL to initiate ART for patients with this clinical stage were compared with 
those using CD4 counts of 250 cells/µL or more. 
Patient-provider ratio  
Patient-provider ratio was calculated for each site as the total number of patients on ART 
during the first quarter of 2008 divided by the total number of days providers are available. The 
first quarter of 2008 was chosen because it was the time closest to when 1) the provider 
information was collected and 2) all the sites had patients on ART.  Note that the patient-
provider ratio category of 12-35.53 was made considerably wider than the other three (ratios 0-
4.0, 4.01-8.5, 8.6-11.99) to include the outlier value of 35.52; otherwise the range would have 
only extended to 18.54.  Selection of the categories was based on the objective of dividing the 
sites into subgroups each with an equal number of sites of similar patient-provider ratios to 
minimize residual confounding [141].   
Fees for Services, ARV Stockouts, Frequency of CD4 Cell Monitoring  
Since there was virtually no variability in the responses, the following constructs were not 
considered for statistical adjustment: charging fees for services rendered (laboratory tests, first 
line ART, opportunistic infection prophylaxis, opportunistic infection treatment, routine follow-
up care, and transportation to the clinic), experiencing ARV disruptions, frequency of CD4 cell 
count monitoring.   
Site-level Variables 
Site Classification 
Sites were also classified as private or public.  Due to a small number of private sites, this 







Assessment of the Statistical Assumptions for Cox Proportional Hazards Models 
The proportional hazards assumption was assessed twice: 1) separately for each variable 
included in the multivariable analysis and 2) while adjusting for other variables in the final 
model. Three different approaches were used: 1) log-log survival curves, 2) goodness of fit test, 
and 3) time-dependent covariates with different versions of time (e.g. survival time, heavyside 
function) in an extended Cox Proportional Hazards model [116].  Categorical variables were 
operationalized as such to produce log-log curves and as indicator variables when creating time-
dependent covariates in extended Cox Proportional Hazards models.  Selection of specific time 
points for heavyside functions were based on inspection of the log-log curves to identify time 
period(s) where the violations of the parallelism were evident [116].  When the proportional 
hazards assumption was assessed for the multivariable analysis, the respective means were used 
as the value for other variables in the model [116].  A variable was assumed to meet the 
proportional hazards assumption unless the log-log curves alone or both the goodness of fit test 
and the time-dependent assessment showed strong evidence of violation [116].  Except for the 
potential mediator, none of the variables tested show evidence of considerable violation of the 
proportional hazards assumption. 
  The linearity assumption for continuous variables patient-provide ratio and age at ART 
initiation was assessed separately for each variable using two approaches.  We fitted a model 
with both a continuous and a squared-term version of the covariate and tested the statistical 
significance (using alpha = 0.05) of the squared-terms.  Secondly, we fitted a bivariable Cox 
model of the outcome and covariate.  Patient-provider ratio was modeled using three indicator 





group), and 12-35.53), and age at ART initiation using eight indicator variables of five-year 
increments for the nine categories (18-23; 24-29; 30-35 (reference group)…66-88).  The 
estimated beta estimates for the indicator variables were plotted and assessed for evidence of a 
linear pattern.  Based on the results of these assessments, patient-provider ratio and age at ART 
initiation were operationalized using three and eight indicator variables, respectively. 
Results 
 Sensitivity Analysis 
Table 8. Key Statistics Used in Selecting the Final Active Screening Entry-Point (ASEP) Cox 
Proportional Hazards Model  
 
    ASEP HR   Akaike Information    
Model     95% CI (width)  Criterion 
 
Standard   0.82    62995.12 
    0.64-1.06 (0.42) 
 
Standard    0.87    47285.52   
(Kenya Sites Only)  0.70-1.08 (0.38) 
 
Stratified Cox Model:  0.82    57506.04 
Patient-Provider Ratio, g=4 0.64-1.06 (0.42) 
 
Stratified Cox Model:  0.83    56400.09 








Table 9. Assessment of Mediation with Final Active Screening Entry Point Model (Model 5) 
Operationalizing CD4 Cell Count at ART Initiation (potential mediator) as a Continuous, 
Quartiles and Dichotomous Variable. 
     ASEP   Percent Change in Beta Estimate 
Model     Beta Estimate  [(Crude-Adjusted/Crude)*100] 
 
Final Active Screening  -0.19605   Reference 
Entry Point Model 
 
Final Active Screening  
Entry Point Model Fitted   
With CD4 Cell Count at  
ART Initiation as: 
Continuous   -0.06916   64.7% 
Quartiles   -0.06955   64.5% 









 Table 10. Proportion of Patients Lost to Follow-up or Recorded as Dead Within a Year Following ART Initiation Among Sites with 
Mainly Active and non-Active Screening Entry Points.  
                       Active Screening  non-Active Screening  OR  
        Entry Points   Entry Points   (95% CI)  
        N=24,725   N=20,616    
     
Number (%) of Patients Lost to Follow-up   
Within a Year of ART Initiation    4,755 (19.2%)   3,925 (19.0%)   1.0 (0.7-1.5) 
 
Number (%) of Recorded Death Within a  
Year of ART Initiation     1,485 (6.0%)   984 (4.8%)   1.0 (0.6-1.8) 
     
 
 
Table 11. Average Value of Last Recorded CD4 and of CD4 at ART Initiation for Patients Who Were Lost to Follow-up Within a 
Year After ART Initiation.  
                        
Active Screening  non-Active Screening  P-Value  
        Entry Points   Entry Points     
        N=4,755   N=3,925 
  
Mean CD4 Value Last Recorded CD4   112.8 cells/µL   92.0 cells/µL   0.0451 
(N (%))       (4,219 (88.7%))  (3,351(92.0%))   
 
Mean CD4 Value at ART Initiation    84.0 cells/µL   73.2 cells/µL   0.06 
(N (%))       (3,925(82.5%))  (3,048(77.7%))    









Table 12. Results of Final Model Cox Model (Model 5) Assuming that all Patients Lost to 
Follow-Up, Within a Year of ART initiation, at Active Screening Entry Point Sites were Alive 
and Those From non-Active Screening Entry Point Sites Died.   
 
Model 5 (Final Model)   
Parameter      HR (95% CI)      
Active Screening Entry Points  0.27 (0.24-0.29)      
(Yes vs. No) 
 
Sex      1.31 (1.25-1.37)         
(Male vs Female)         
 
Sites by Type 
Health Center/Clinic vs  0.90 (0.81-1.00)        
District/Provincial Hospitals 
 
Teaching/National   1.13 (0.99-1.30)    
 Referral Hospital vs    
 District/Provincial Hospitals 
 
Site Patient-Provider Ratio           
0-4.0 vs 8.6-11.99   0.84 (0.64-1.10) 
 4.01-8.5 vs 8.6-11.99   0.98 (0.86-1.11)        
 12-35.33 vs 8.6-11.99   1.18 (1.05-1.32)     
 
Patient Waiting List    1.31 (1.09-1.56) 
(Yes vs No) 
 
Predominant Patient Population Served 
Rural vs Urban   0.76 (0.67-0.86) 
In Between Urban/Rural vs   0.77 (0.70-0.85) 
Urban 
 
Site’s ART Eligibility Criterion for  0.74 (0.62-0.89)  
Patients in WHO Clinical Stage 1 or 2  











Table 13. Results of Final Model Cox Model (Model 5) Assuming that all Patients Lost to 
Follow-Up, Within a Year of ART initiation, at Active Screening Entry Point Sites Died and 
Those From non-Active Screening Entry Point Sites were Alive.   
 
Model 5 (Final Model)   
Parameter      HR (95% CI)      
Active Screening Entry Points  3.25 (2.28-4.63)      
(Yes vs. No) 
 
Sex      1.22 (1.15-1.30)         
(Male vs Female)         
 
Sites by Type 
Health Center/Clinic vs  0.85 (0.69-1.04)        
District/Provincial Hospitals 
 
Teaching/National   1.40 (0.90-2.18)    
 Referral Hospital vs    
 District/Provincial Hospitals 
 
Site Patient-Provider Ratio           
0-4.0 vs 8.6-11.99   1.42 (0.71-2.83) 
 4.01-8.5 vs 8.6-11.99   0.96 (0.67-1.36)        
 12-35.33 vs 8.6-11.99   1.02 (0.88-1.19)     
 
Patient Waiting List    3.05 (2.42-3.84) 
(Yes vs No) 
 
Predominant Patient Population Served 
Rural vs Urban   1.23 (0.84-1.80) 
In Between Urban/Rural vs   0.99 (0.86-1.15) 
Urban 
 
Site’s ART Eligibility Criterion for  0.35 (0.25-0.50)  
Patients in WHO Clinical Stage 1 or 2  























IeDEA Site Assessment Tool 
IeDEA East Africa Brief Follow-up Questionnaire 
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